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ABSTRACT 
Stabilization of the Cardiac Nervous System During Cardiac Stress Induces Cardioprotection 
by 
David D. Gibbons 
 
The cardiac nervous system consists of nested reflex feedback loops that interact to regulate regional 
heart function.  Cardiac disease affects multiple components of the cardiac nervous system and the 
myocytes themselves.  This study aims to determine: 1) how select components of the cardiac 
nervous system respond to acute cardiac stress, including myocardial ischemia (MI) and induced 
neural imbalance leading to cardiac electrical instability, and 2) how neuromodulation can affect 
neural-myocyte interactions to induce cardioprotection.  Thoracic spinal cord stimulation (SCS) is 
recognized for its anti-anginal effects and ability to reduce apoptosis in response to acute MI, 
primarily via modulation of adrenergic efferent systems.  The data presented here suggest that 
cervical SCS exerts similar cardioprotective effects in response to MI, but in contradistinction to 
thoracic SCS, uses both adrenergic and cholinergic efferent mechanisms to stabilize cardiomyocytes 
and the arrhythmogenic potential.  SCS potentially can use efferent and/or anti-dromically activated 
cardiac afferents to mediate its cardioprotection.  Thoracic SCS mitigates the MI-induced activation 
of both nodose and dorsal root ganglia cardiac-related afferents, doing so without antidromic 
activation of the primary cardiac afferents.  Instead, thoracic SCS acts through altering the cardiac 
milieu thereby secondarily affecting the primary afferent sensory transduction.  In response to 
cardiac stressors, reflex activation of efferent activity modifies mechanical and electrical functions of 
the heart.  Excessive activation of neuronal input to the cardiac nervous system can induce 
arrhythmias.  Stimulation of intrathoracic mediastinal nerves directly activates subpopulations of 
intrinsic cardiac neurons, thereby inducing atrial arrhythmias.  Neuromodulation, either thoracic SCS 
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or hexamethonium, suppressed mediastinal nerve stimulation (MSNS)-induced activation of intrinsic 
cardiac neurons and correspondingly reduced the arrhythmogenic potential.  SCS exerted its 
stabilizing effects on neural processing and subsequent effects on atrial electrical function by 
selectively targeting local circuit neurons within the intrinsic cardiac nervous system.  Together these 
data indicate that neuromodulation therapy, using SCS, can mitigate the imbalances in cardiac reflex 
control arising from acute cardiac stress and thereby has the potential to slow the progression of 
chronic heart disease.  
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CHAPTER 1 
INTRODUCTION 
 
The Cardiac Nervous System 
The cardiac nervous system is a subdivision of the autonomic nervous system, which 
includes the sympathetic and parasympathetic efferent branches.  It functions to reflexly control 
physiological functions like heart rate, cardiac contractility, and more.  The cardiac nervous system 
consists of afferent, efferent, and multiple processing neuronal networks, including those located 
within the central nervous system (CNS) and within peripheral ganglia (Armour 1999; 2004).  The 
afferent neurons transduce cardiac sensory information to the cardiac nervous system using 
intracardiac (intrinsic cardiac nervous system) and extracardiac (stellate, middle cervical, nodose, and 
dorsal root) ganglia (Armour 1986a; 1986b; Bosnjak and Kampine 1989; Brown 1967; Hopkins and 
Armour 1989; Horackova and others 1996; Kuo and others 1984).  Afferent input provided to the 
cardiac nervous system includes that from arterial baroreceptors, chemoreceptors (cardiac and 
peripheral), and multimodal cardiopulmonary and somatic afferents (Armour 1999; 2004).  For 
cardiac control, the parasympathetic preganglionic neurons originate in the nucleus ambiguus and 
the dorsal motor nucleus in the medulla oblongata and travel through the cranial nerve to synapse 
on postganglionic parasympathetic neurons contained within the intrinsic cardiac ganglia (Cheng and 
others 1999; Hopkins and Armour 1984; Plecha and others 1988).  For cardiac control, the 
sympathetic preganglionic neurons originate from the intermediolateral cell column of the spinal 
cord, exiting at the T1-T5 levels, to synapse with postganglionic neurons in the intrathoracic-
extracardiac ganglia and the intrinsic cardiac ganglionated plexuses (Forsgren and others 1990; 
Hopkins and Armour 1984; Horackova and others 1999; Moravec and Moravec 1987). 
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The intrinsic cardiac and other intrathoracic autonomic ganglia contain local circuit neurons 
(LCN).  The primary function of this neural population is to interconnect afferent and efferent 
neural components within and between intrathoracic autonomic ganglia (Armour 1999; 2004; 2008).  
Peripheral neural interconnections are thought to contribute to organ level processing and 
functional control (Armour 1986a; Armour 1991; Armour and Janes 1988; Armour and others 1997; 
Darvesh and others 1987; Yuan and others 1994).  Cardiac function is regulated by the interactions 
between central and peripheral neuronal components of the cardiac nervous system (Armour 2004).  
These interactions are manifest as interdependent feedback loops between intracardiac and 
extracardiac ganglia, spinal cord, brainstem, and higher centers of the central nervous system 
(Armour 2004).  The intrinsic cardiac nervous system is thought to control short-term function, with 
longer-term function being controlled by progressively higher neural networks (Armour 1999; 2004; 
2008).  These interdependent networks interact ultimately to control the autonomic efferent 
outflows via the sympathetic and parasympathetic nervous systems (Armour 2004). 
Parasympathetic activation decreases cardiac chronotropism (rate), dromotropism 
(conduction), and inotropism (contractility), while sympathetic activation exerts opposite effects 
(Burwash and others 1993; Randall and others 1996).  Normal cardiac function is also regulated 
through the influence of circulating hormones, such as angiotensin II, and circulating 
catecholamines acting on both neural components and the cardiac end-effectors (Ardell 2004).  
Figure 1 summarizes many of the salient neurohumoral interactions that ultimately result in control 
of cardiac function in the normal and stressed heart. 
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Figure 1.1.  A schematic of the neurohumoral components and their interactions that contribute to 
the control of heart function. DRG – dorsal root ganglia. LCN – local circuit neurons. Aff. – 
afferent. C1-C2 – Cervical spinal segments 1-2. T1-T4 – Thoracic spinal segments 1-4. Ang I – 
Angiotensin I. Ang II – Angiotension II. β1 – Beta 1-adrenergic receptors. M2 – Muscarinic 
receptors subtype 2. ATP – Adenosine triphosphate. cAMP – Cyclic adenosine monophosphate. Gs 
– Gs-protein subunit. Gi – Gi-protein subunit. AC – Adenylate cyclase. (adapted from Ardell and 
Foreman 2009) 
Ischemic Cardiac Disease and Its Effect on the Cardiac Nervous System 
Approximately every minute an American dies from a coronary event making coronary heart 
disease a significant health concern for a large portion of the U.S. population (Lloyd-Jones and 
others 2009).  The incidence of coronary heart disease, including acute coronary syndrome, is 
estimated at 935,000 new and recurrent attacks in the U.S. per year (Lloyd-Jones and others 2009).  
Restricting the supply of blood and oxygen to the heart leads to myocardial ischemia (Thygesen and 
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others 2007).  Acute coronary syndrome consists of MI and angina pectoris (Thygesen and others 
2007).  If severe enough, MI induces changes in the cardiac environment including increasing the 
propensity for arrhythmia formation, cardiac cell death, and the potential for progression into heart 
failure (Thygesen and others 2007). 
Disease states alter multiple components of the cardiac nervous system (Armour 1999).  
Cardiac afferent neurons are thought to be the first component affected.  For example, regional 
ventricular ischemia increases cardiac sensory activity via activating multimodal cardiac sensory 
neurites (Armour 1999; Huang and others 1996).  MI reflexly activates intrinsic cardiac neurons 
leading to adverse function such as arrhythmia formation and compromised mechanical activity 
(Foreman and others 2000).  MI likewise causes the reflex activation of efferent neurons in the 
stellate and middle cervical ganglia, contributing to the increase in postganglionic sympathetic 
activity (Ardell and others 2009).  Central processing of afferent inputs at the level of the spinal cord 
and brainstem contribute to reflex evoked changes in efferent outflows (Armour 1999; 2004).  
Research into the effects of MI on the heart and the cardiac nervous system has identified two 
distinct sets of effects, short-term and long-term (Armour 1999; 2004).  In the short term, excessive 
reflex activation of parasympathetic and sympathetic efferent neurons can elicit atrial or ventricular 
arrhythmias (Armour 1976; Armour and others 2005; Cardinal 2004; Carlson and others 1992; 
Huang and others 1994; Schwartz and others 1978).  Excessive catecholamine release, in reflex 
response to ischemia, is also cardio-toxic (Armour 1999).  Over longer periods of time, cardiac 
disease induces neural remodeling of the cardiac nervous system (and heart tissues) and this 
contributes to the progression of cardiac pathologies (Armour 1999; 2004).  Examples of neural 
remodeling include focal denervation of nerve projections through the infarct zone and 
hyperinnervation in the border zone surrounding the region of ischemic insult (Chen and others 
2001).  Changes in innervation density can be accompanied by focal changes in receptor density, 
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receptor coupling and neurotransmitter release (Chen and others 2007; Chen and others 2001; Zipes 
2008).  Heterogeneity in efferent inputs to the heart are a major contributor to adverse 
consequences of cardiac disease (Armour 2004). 
Cardiac Arrhythmias and the Cardiac Nervous System 
Heterogeneous efferent input to the heart is a major risk factor for cardiac arrhythmias 
(Armour 2004; Zipes 2008).  In normal hearts, the sympathetic and parasympathetic nervous 
systems form a interdependent neural substrate to regulate regional cardiac electrical activity 
(Armour 2004).  MI-induced alterations in cardiac tissues by themselves directly increase the 
arrhythmogenic substrate of the heart (Armour 2004).  For example, myocardial infarct disrupts 
electrical pathways within the heart, leading to arrhythmia formation through reentrant circuits 
(Iwasaki and others 2011).  These reentrant circuits are self-perpetuating waves of cardiac electrical 
activity that result in the formation of cardiac arrhythmias, including tachycardia and fibrillation 
(Armour 1999; Iwasaki and others 2011).  Superimposed on the alterations of electrical substrate, 
imbalances of neuronal control can facilitate arrhythmia formation (Armour 1999).  Recent evidence 
suggests that nerve sprouting in and near the infarct site can contribute to this imbalance of neural 
control (Chen and others 2001).  MI-induced nerve sprouting is found predominantly in sympathetic 
nerves (Chen and others 2001), likely contributing to imbalanced neurotransmitter release during MI 
stress (Zipes 2008).  Heterogeneous adrenergic neural activity evokes imbalances in myocyte 
excitability and refractoriness, both contributing to cardiac electrical instability (Zipes 2008).  These 
data point to the interdependence of neural and local myocyte factors in the electrical stability of 
normal and ischemic stressed hearts (Zipes 2008). Therapies that reduce the heterogeneity, either by 
targeting the myocyte substrate or the neural mechanisms that modulate it, should translate into 
decreased risk of cardiac arrhythmias (Zipes 2008). 
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Recent studies have used an experimental model of electrically-induced atrial fibrillation (AF) 
to study cardiac arrhythmia formation and mechanisms to control them (Armour and others 2005; 
Cardinal and others 2006; Richer and others 2008).  One model involves stimulating mediastinal 
nerves that course over the ventral and ventrolateral surfaces of the superior vena cava (Armour and 
others 2005).  Stimulation of these nerves creates self-terminating periods of AF (Armour and 
others 2005).  While this model differs in some respect from cardiac disease-created AF, it allows for 
the study of how neuronal imbalances within the cardiac nervous system can influence the 
formation of arrhythmias and potentially how aspects of that neural population can be targeted to 
modulate the potential for AF (Armour and others 2005; Cardinal and others 2006; Richer and 
others 2008). 
Neuromodulation as a Novel Approach to Treat Heart Disease 
Cardiac disease is a multi-factored process that involves cardiac tissues and the 
neurohumoral factors that modulate the heart (Armour 1999; 2004).  Cardiac dysfunction, as occurs 
in acute coronary syndrome, can be targeted by therapies directed at cardiomyocytes, the 
neurohumoral components that regulate them or by physical means as with restoration of blood 
flow (Armour 1999; 2004).  Coronary artery bypass graft and balloon angioplasty are the primary 
mechanical therapies that restore blood flow and are effective in a majority of patients (Andrade and 
others 2011; Mannheimer and others 1998).  However, a subset of patients are not candidates for 
such an approach or conversely, exhibit refractory angina even after revascularization (Mannheimer 
and others 1998). 
Neuromodulation-based therapies for cardiac disease focus on targeting neuronal 
components within the cardiac nervous system to achieve effects.  One such neuromodulatory 
approach involves cryo- or electrical ablation of specific neuronal targets of the intrinsic cardiac 
nervous system as an adjunct therapy to traditional ablation of cardiomyocytes to control atrial 
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arrhythmias (Burkhardt and Natale 2009).  This therapy is predicated on the hypothesis that 
disruption of select parts of the cardiac nervous system can stabilize the heart and reduce the 
arrhythmogenic potential of the heart (Armour 2008).  The resulting lesions eliminate 
subcomponents of the neural networks that influence cardiac function, but the potential for sudden 
cardiac death (SCD) still remains (Armour 2008).  Importantly, while ablation therapy has shown 
some positive short-term effects, the interconnectivity and processing ability of remaining parts of 
the cardiac nervous system along with their remodeling post-ablation allows for those remaining 
components of the cardiac nervous system to still promote the formation of arrhythmias in the long 
term (Armour 2008). 
Neuromodulation therapy can use pharmacological blockade of receptors to impact 
neuronal activity (Armour 1999; Association 2007; Marieb 2004).  These pharmacological 
approaches can consist of agents like non-selective β-adrenergic antagonists or specific agents like α- 
or β1-selective adrenergic receptor blockers (Association 2007).  While pharmacological therapies 
can be effective in combating cardiac dysfunction including progression into congestive heart failure 
and potential for SCD (Association 2007), the cardiac nervous system isn’t the only target of these 
pharmacologically based therapies (Marieb 2004).  The neuropharmacologically-based therapies 
often result in numerous unwanted side effects, such as diarrhea, rash, slow heart rate, and 
impotence, reducing the indications for use and are also subject to patient non-compliance 
(Association 2007). 
An emerging neuromodulation therapy involves electrical stimulation of various aspects of 
the cardiac nervous system to treat cardiac pathophysiology.  For example, vagal nerve stimulation is 
currently being evaluated to treat heart failure (Schwartz and De Ferrari 2009).  This approach is 
predicated on the hypothesis that increasing parasympathetic tone will counteract the increase in 
sympathetic activity seen in heart failure and thereby slow progression of congestive heart failure 
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(Schwartz and De Ferrari 2009).  In one study of animals with healed infarcts, vagal stimulation 
reduced heart rate by 75 beats per minute during exercise and reduced the propensity for ventricular 
fibrillation from 92% in control to 12% during the exercise stress (Vanoli and others 1991).  Recent 
studies also have shown that low-level vagal nerve stimulation reduces the arrhythmogenic potential 
of the atria in response to rapid atrial pacing while also reducing sympathetic nerve activity (Sha and 
others 2011; Shen and others 2011b).  These studies indicate that induced alterations in autonomic 
efferent outflows can be moderated by electrical neuromodulation to affect cardiac electrical stability 
(Zipes 2008). 
Another approach for neuromodulation involves direct electrical stimulation of the carotid 
baroreceptors.  This therapy is predicated on the hypothesis that increased baroreceptor activity will 
reflexly increase parasympathetic activity and decrease sympathetic activation to the heart (Sabbah 
and others 2011; Wang and others 1991; Zucker and others 2007). This therapy elicited a reduction 
in the progression of congestive heart failure in response to the cardiac stress of rapid ventricular 
pacing (Zucker and others 2007).  It remains to be determined if such an integrated baroreflex type 
approach is effective against other models of cardiac disease (e.g. MI, mitral regurgitation, etc.). 
A third major approach using electrical neuromodulation involves spinal cord stimulation 
(SCS).  In the treatment of heart disease, SCS is traditionally performed at the T1-T3 levels with 
electrical stimuli applied to the dorsal aspects of the spinal cord.  This level includes the spinal 
segments where the sympathetic efferent nerve fibers exit and the cardiac sympathetic afferent nerve 
fibers enter the spinal cord from the heart (Armour 1999; 2004).  Clinical research has demonstrated 
that high thoracic SCS significantly reduces the presentation of anginal symptoms, the onset of 
angina and increases exercise tolerance (Mannheimer and others 1993; Mannheimer and others 
1998; Sanderson and others 1992; Sanderson and others 1994).  In addition, SCS decreased the ST-
segment depression, a marker of MI, and increased the time before ST-segment depression onset 
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during a progressive exercise stress test (Eliasson and others 1993; Mannheimer and others 1993; 
Sanderson and others 1992; Sanderson and others 1994).  Clinical investigators have suggested that 
the cardiac benefits of SCS result from improved oxygen supply/demand balance in the stressed 
heart (Mobilia and others 1998), but little hard evidence has been put forth to support this concept 
(Kingma and others 2001). 
Basic science research has confirmed and extended the potential cardioprotective effects 
evoked by SCS (Ardell and others 2009; Armour and others 2002; Armour and others 2005; 
Cardinal and others 2006; Foreman and others 2000; Qin and others 2008; Richer and others 2008; 
Southerland and others 2007).  High thoracic SCS has been shown to decrease MI-induced 
sympathetic activation in reflex response to ischemic stress and to reduce the arrhythmogenic 
potential resulting from ischemic stress (Ardell and others 2009; Cardinal and others 2006; 
Southerland and others 2007).  Other studies have demonstrated that SCS modulates activity in the 
middle cervical and intrinsic cardiac ganglia and within the spinal cord, attenuating their reflex 
response to ischemic stress (Ardell and others 2009; Ding and others 2008a; Ding and others 2008b; 
Foreman and others 2000; Qin and others 2008; Southerland and others 2007).  Pre-emptive SCS 
likewise activates protein kinase C in ventricular myocytes, contributing to the cardioprotective 
effects against the stress of acute MI (Southerland and others 2007).  High thoracic SCS-induced 
cardioprotection to ischemic stress occurs without significant changes in cardiac blood flow and 
without significant changes in basic hemodynamic function (Kingma and others 2001).  Transection 
of the ansae subclavian, eliminating afferent and efferent interconnections between the spinal cord 
and peripheral aspects of the cardiac nervous system, prevents SCS-induced changes in middle 
cervical and intrinsic cardiac neuronal activity (Cardinal and others 2006; Foreman and others 2000).  
These data demonstrate that thoracic SCS exerts many of its beneficial effects on cardiac function 
by; 1) targeting the cardiac nervous system and 2) directly impacting cardiac tissue (Ardell and others 
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2009; Armour 2008; Armour and others 2002; Armour and others 2005; Cardinal and others 2006; 
Foreman and others 2000; Southerland and others 2007). 
The targeting of neural elements that regulate cardiac function was initially evaluated at the 
high thoracic spinal cord level, where the sympathetic efferent and afferent neurons enter and exit 
the cord (Ding and others 2008a; Ding and others 2008b; Qin and others 2008).  This high thoracic 
location mitigates numerous deleterious effects induced by cardiac ischemic pathologies (Ardell and 
others 2009; Armour and others 2002; Cardinal and others 2006; Foreman and others 2000; 
Southerland and others 2007).  Recent anatomical and functional studies have indicated that there 
may be other potential sites within the neural hierarchy for cardiac control where SCS may exert 
cardioprotective effects in response to cardiac stress (Ding and others 2008b; Qin and others 2008).  
The high cervical region of the spinal cord is one such site.  The high cervical spinal segments 
receive parasympathetic and sympathetic afferent nociceptive inputs (Chandler and others 1996; 
Chandler and others 2000; Foreman 1999).  It is also reciprocally interconnected with lower levels of 
the spinal cord and with supraspinal elements of the cardiac nervous system (Marieb 2004).  
Previous work has indicated that high cervical SCS attenuates afferent transduction of cardiac 
ischemia (Ding and others 2008b; Gonzalez-Darder and others 1991; Qin and others 2008).  The 
high cervical spinal segments also modulate spinal cord reflex processing of autonomic outflow for 
thoracic and visceral tissues (Ding and others 2008a; Ding and others 2008b; Qin and others 2007a; 
Qin and others 2008; Qin and others 2007b).  These findings indicate that high cervical spinal 
segments may therefore provide a site higher in the cardiac neural hierarchy for SCS to act upon 
(Ding and others 2008b; Qin and others 2008). 
To investigate the specific neuronal targets of neuromodulation, this dissertation is 
predicated on the following hypotheses: 1) The cardiac nervous system contains a complex hierarchy 
of reflex control systems that contribute to control of regional cardiac function; 2) The cardiac 
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nervous system is disrupted by cardiac stressors contributing to deleterious effects on that neural 
control system and the myocardium it modulates; and 3) Stabilization of select aspects of the cardiac 
nervous system through neuromodulation can mitigate the deleterious effects of cardiac stressors on 
the neural components of the cardiac nervous system and the myocardium thereby inducing states 
of cardioprotection.  To test these hypotheses, this dissertation was divided into three specific aims 
which are as follows. 
Specific Aims 
Specific Aim 1: To determine whether high cervical cord neurons can modify infarct size 
and potential for SCD in response to ischemic stress. 
Myocardial ischemia is known to impact cardiomyocytes directly and the cardiac nervous 
system that controls them (Armour 2008).  High thoracic SCS has recently been shown to have anti-
ischemic properties that improve the ability of the heart to function following MI (Cardinal and 
others 2004; Eliasson and others 1993; Mannheimer and others 1993).  Pre-emptive thoracic SCS 
reduces infarct size as well as activates cardiomyocyte protein kinase C pathways (Southerland and 
others 2007). It also stabilizes the electrical properties of the ventricle in response to transient MI 
(Cardinal and others 2004; Southerland and others 2007).  Neurons in the upper cervical spinal cord 
are known to modify sensory transduction from the periphery, including those arising from the 
thorax and viscera (Chandler and others 1993; Ding and others 2008b; Foreman and others 2004).  
Pre-emptive SCS from the high cervical region modulates dorsal horn sensory afferent signaling 
from the ischemic myocardium (Ding and others 2008a).  This effect may reflect activity of cervical 
propriospinal pathways that release dynorphin at the thoracic spinal cord to modulate nociceptive 
signaling (Ding and others 2008b).  The C1-C2 region is interconnected with lower levels of the 
cord and with cardiovascular regions of the brainstem, including the nucleus tractus solitarii 
(Chandler and others 1993; Ding and others 2008b; Foreman and others 2004).  These data indicate 
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the potential of the upper cervical spinal segments to act as a processing center within the cardiac 
neuronal hierarchy for cardiac control and a site for potentially modifying the deleterious cardiac 
effects of MI (Ding and others 2008a; Qin and others 2008).  Chapter 2 will focus on the hypothesis 
that high cervical SCS neuromodulation imparts cardioprotective effects in response to MI by 
modulating sympathetic and parasympathetic outflows to the heart.  Cardioprotective effects 
evaluated will include infarct size and the potential for MI-induced SCD.  This aim will determine if 
those cardioprotective effects involve 1) descending projections from the cervical to the thoracic 
spinal cord and 2) the differential roles of high cervical SCS-mediated changes in sympathetic versus 
parasympathetic efferent outflows and their response to acute MI.  
Specific Aim 2: To determine if SCS modulates primary afferent neural transduction of MI. 
SCS has been shown to modulate the MI-induced increase in activity of neurons in 
intrathoracic ganglia (Ardell and others 2009).  These ganglia, including intrinsic and extracardiac 
ones, contain cardiac efferent and afferent and local circuit neurons (Ardell and others 2009; 
Foreman and others 2000).  SCS does not interrupt primary efferent projections to the heart 
(Armour and others 2002).  Within peripheral ganglia of the cardiac nervous system, data indicate 
that SCS may target the local circuit neurons to blunt reflex activation of autonomic efferent outflow 
(Ardell and others 2009; Armour 2008; Foreman and others 2000; Qin and others 2008).  Primary 
cardiac afferent neurons and their response to MI in association with SCS neuromodulation have yet 
to be studied. 
Previous studies identifying SCS effects on cutaneous blood flow have suggested that SCS 
can impose an “efferent” function on afferent neurons (White and Helme 1985).  Whether such 
antidromic evoked responses are manifested in cardiac afferents in response to SCS have yet to be 
determined.  Chapter 3 will examine the hypothesis that high thoracic SCS modifies the ability of 
primary cardiac afferent neurons to respond to the stress of MI, either by direct antidromic 
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activation of primary cardiac afferent neurons or through altering the cardiac sensory milieu.  To 
investigate this hypothesis, the activity of primary cardiac afferent neurons (nodose and DRG) will 
be examined in response to transient MI, with and without pre-emptive SCS neuromodulation. 
Specific Aim 3: To determine if SCS targets intrinsic cardiac neurons to attenuate 
neuronally-mediated atrial arrhythmias. 
Excessive activation of discrete inputs to the intrinsic cardiac nervous system have been 
demonstrated to create atrial arrhythmias in normal and diseased states (Armour and others 2005; 
Choi and others 2011; Richer and others 2008; Shen and others 2011a).  As described previously, the 
stimulation of select intrathoracic mediastinal nerves evokes reproducible and self-terminating 
periods of AF (Armour and others 2005).  This model of AF is known to involve both 
parasympathetic and sympathetic efferent mechanisms (Armour and others 2005; Richer and others 
2008).  SCS has previously been shown to decrease the induction of AF following mediastinal nerve 
stimulation (MSNS), but the neural mechanisms underlying this response have not been determined 
(Cardinal and others 2006).  Therefore, Chapter 4 will investigate the hypotheses that: 1) MSNS 
activates select neuronal subpopulations within the intrinsic cardiac nervous system (ICN) in 
association with the induction of AF; 2) stabilization of those populations within the intrinsic cardiac 
nervous system via neuromodulation (electrical or pharmacological) blunts the capacity of the ICN 
to respond to excessive inputs; and 3) stabilization of intrinsic cardiac neurons suppresses the atrial 
arrhythmogenic potential.  The neurochemical phenotype and activity of right atrial ganglionated 
plexus neurons along with AF induction characteristics in response to MSNS and neuromodulation, 
electrical or pharmacological, will be examined to test this hypothesis. 
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Abstract 
To evaluate whether cervical spinal neurons can influence cardiac indices and myocyte 
viability in the acutely ischemic heart, the hearts of anesthetized rabbits subjected to 30 min of left 
anterior descending (LAD) coronary arterial occlusion (CAO) were studied 3 hours after 
reperfusion. Control animals were compared to those exposed to pre-emptive high cervical cord 
stimulation (SCS; the dorsal aspect of the C1-C2 spinal cord was stimulated electrically at 50 Hz; 0.2 
ms; 90% of motor threshold, starting 15 min. prior to and continuing throughout CAO).  Four 
groups of animals were so tested: 1) neuroaxis intact; 2) prior cervical vagotomy; 3) prior transection 
of the dorsal spinal columns at C6; and 4) following pharmacological treatment [muscarinic 
(atropine) or adrenergic (atenolol, prazosin or yohimbine) receptor blockade]. Infarct size (IS) was 
measured by tetrazolium expressed as percentage of risk zone.  C1-C2 SCS reduced acute ischemia 
induced IS by 43%, without changing the incidence of sudden cardiac death (SCD).  While SCS-
induced reduction in IS was unaffected by vagotomy, it was no longer evident following transection 
of C6 dorsal columns or atropinization.  Beta-adrenoceptor blockade eliminated ischemia-induced 
SCD, while alpha-receptor blockade doubled its incidence.  During SCS, myocardial ischemia 
induced SCD was eliminated following vagotomy while remaining unaffected by atropinization.  
These data indicate that, in contrast to thoracic spinal neurons, 1) cranial cervical spinal neurons 
affect both adrenergic and cholinergic motor outflows to the heart such that 2) their activation 
modifies ventricular infarct size and lethal arrhythmogenesis.    
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Introduction   
 Myocardial ischemia represents a complex cardiovascular stress that involves cardiomyocytes 
as well as neurohumoral control of cardiomyocytes (Kajstura et al., 2006; Armour, 2008).  
Imbalances in such neurohumoral control, especially those leading to excessive sympathetic efferent 
neuronal activation, have been associated with an enhanced arrhythmogenic substrate (Schwartz, 
2001) as well as deterioration of pump function (Armour, 2008; Dell'Italia & Ardell, 2004).  
Conversely, endogenous or exogenous mechanisms that maintain parasympathetic efferent neuronal 
control during transient myocardial ischemia have been proposed to exert cardioprotective effects - 
thereby reducing any risk of sudden cardiac death (Vanoli et al., 2008).   
 Neuromodulation-based therapies that underlie the emerging field of neurocardiology are 
known to affect the progression of cardiac pathologies.  For instance, pharmacological therapies that 
employ β-adrenoceptor blockade and/or angiotensin-converting enzyme inhibition (Hankes et al., 
2006; Perry et al., 2002) modulate not only cardiomyocyte function directly, but also indirectly by 
mitigating adverse remodeling of the cardiac neuronal hierarchy (Armour, 2008; Hankes et al., 2006; 
Tallaj et al., 2003). 
Spinal cord stimulation (SCS) has been reported to exhibit anti-ischemic properties that 
include increased exercise tolerance (Hautvast et al., 1998), diminished ST segment deviation during 
stress (Cardinal et al., 2004; Hautvast et al., 1998; Odenstedt et al., 2011), and improved lactate 
metabolism (Mannheimer et al., 2002).  Yet, anginal pain can still be evoked in the presence of SCS 
when the stress (e.g. exercise) is of sufficient magnitude to induce critical levels of myocardial 
ischemia (Eddicks et al., 2007; Mannheimer et al., 2002). 
Evidence indicates that neurons in the thoracic spinal cord play a role in processing afferent 
inputs arising from the stressed heart (Ding et al., 2008a; Ding et al., 2008b).  In fact, electrical stimuli 
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delivered to neurons within the thoracic spinal cord have been shown to reduce electrical instability 
of the stressed ventricle (Cardinal et al., 2004; Cardinal et al., 2006; Odenstedt et al., 2011).  We have 
proposed that the cardioprotection elicited by delivering pre-emptive electrical stimuli to the 
thoracic spinal cord acts to stabilize excessively active intrinsic cardiac local circuit neurons involved 
in transducing the ischemic event (Armour, 1997; Armour et al., 2002).  Such therapy also activates 
cardiomyocyte protein kinase C (PKC) pathways and reduces infarct size in response to transient 
periods of myocardial ischemia (Southerland et al., 2007). 
Neurons in the C1-C2 spinal cord are known to be involved in modifying pain transmission 
arising from intrathoracic and abdominal viscera (González-Darder et al., 1991) presumably because 
to the fact that they receive afferent neuronal inputs from sympathetic ascending projections and 
nodose ganglion neurons (Chandler et al., 1993; Ding et al., 2008a).  In addition, the C1-C2 spinal 
cord region is known to be interconnected reciprocally with cardiovascular-related medullary 
neurons (Foreman et al., 2004).  As it remains to be established whether neurons in the cervical spine 
are involved in cardiac neuromodulation and, if so, in what manner, this study was devised to 
determine whether neuromodulation of cervical spinal neurons can affect cardiac indices, 
particularly in the presence of myocardial ischemia.   
If cervical SCS does indeed impart cardioprotection, as manifested by changes in infarct size 
and the potential for sudden cardiac death, we also sought to elucidate whether such 
cardioprotection involves not only 1) cervical spinal descending projections to the thoracic cord, 2) 
but also whether supraspinal projections arising from the C1-C2 region modify parasympathetic 
outflow to impact cardiac function in response to ischemic stress – something not evident from 
thoracic SCS.  Thus we sought to determine whether such a therapeutic intervention might involve 
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adrenergic versus cholinergic efferent neurons from high cervical spinal cord neuronal inputs and 
whether such modulation imparts potential therapeutic benefits to the ischemic ventricle. 
 
Materials and Methods 
 Subjects. One hundred eighty two New Zealand White rabbits of either sex, weighing between 
1.7 and 3.8 kg (2.7±0.4 kg), were used in these studies. Seventeen of these were excluded from final 
analysis for technical reasons.  Because the rabbit heart has minimal collateral blood flow, this 
animal model produces a distinct, homogenous ventricular risk zone, which is ideal to directly 
evaluate therapeutic interventions for transient myocardial ischemia (Maxwell et al., 1987). All 
experiments were performed in accordance with the guidelines for animal experimentation described 
in the “Guiding Principles for Research Involving Animals and Human Beings” 
(Am.Physiol.Society, 2002). The Institutional Animal Care and Use Committee of East Tennessee 
State University approved these experiments.  
 Surgical preparation. Rabbits were anesthetized with intravenous pentobarbital sodium (30 
mg/kg iv via ear access, supplemented as needed with 2 mg/kg iv if the animal responded to 
noxious stimuli or an increase in arterial blood pressure was observed). The trachea was intubated 
via a cervical incision and mechanical ventilation initiated and maintained with a positive pressure 
ventilator (MD Industries, Mobile, AL) using 100% O2. Core body temperature was maintained at 
38˚C via a circulating water heating pad. The right carotid artery was cannulated for monitoring 
blood pressure and the right jugular vein cannulated to administer anesthetic agents and drugs. Heart 
rate was assessed from a Lead II electrocardiogram. All hemodynamic data were recorded 
concurrently on a Gould model TA6000 recorder. For protocols 1d and 3b (fig. 1), both cervical 
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vagi were exposed by a midline cervical skin incision and isolated in order that bilateral vagotomy 
could be performed.  
 Animals were placed in ventral recumbency and a laminectomy was performed at the C2 
level followed by the subdural placement of two plate electrodes (2 x 3 mm) slightly to the left of the 
midline at the C1-C2 level. Spinal cord stimulation (SCS) was performed via these indwelling 
electrodes which were connected to a Grass S88 stimulator (Grass Instruments, Quincy, MA) using 
a constant current stimulus isolation unit (Grass PSIU 6G). The parameters used to stimulate the 
spinal cord were 50 Hz, 0.2 ms duration and at an intensity of 90% of motor threshold. SCS 
stimulation parameters were chosen because of their proven therapeutic benefits (Mannheimer et al., 
2002) including its documented ability to reduce infarct size in response to transient myocardial 
ischemia (Southerland et al., 2007). To determine the adequate stimulus intensity, the current 
intensity was progressively increased until minor muscle contractions were observed in the cervical 
neck region and/or left upper shoulder (motor threshold). Current intensity was set at 90% of 
motor threshold for the experimental protocols; this intensity averaged 0.27 + .07 (SD) mA.  The 
rostral and caudal poles were chosen as cathode and anode, respectively, according to current clinical 
practice (Mannheimer et al., 2002).  Motor threshold determinations were repeated at the end of the 
experimental protocols to determine the stability of the stimuli intensity. For protocols 1c and 3a 
(Fig. 1), an additional laminectomy was performed at the C6 level, and a midline incision was made 
in the spinal cord and extended approximately 2-3 mm laterally on each side to transect the dorsal 
columns of the spinal cord at that level.  
 Animals were rotated to their right-side and a thoracotomy was performed in the left fourth 
intercostal space.  The pericardium was opened to expose the heart. A 2-0 silk suture on a curved, 
tapered needle was passed around the left anterior descending coronary artery one-third of the 
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distance from the left ventricular base to apex. Regional cyanosis and bulging were observed when 
the ends of the suture were pulled through a small polyethylene tube to form a snare, which was 
then secured by clamping the tube with a hemostat. Cyanosis and regional diskinesia were observed 
in the region downstream to the occluded vessel and both disappeared immediately upon 
reperfusion. The risk zone consisted of the myocardial tissue perfused by the snared coronary artery; 
the non-risk zone consisted of the remainder of the left ventricle. A 20-minute stabilization period 
preceded the onset of each experimental protocol.  
Experimental protocols. Figure 1 summarizes the experimental protocols used for each of the 11 
groups of rabbits studied. Each group underwent a dorsal laminectomy at the C2 level prior to being 
subjected to 30 min. of coronary arterial occlusion (CAO) followed by a 3-hr reperfusion period. 
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Figure 1.  Protocols for the in situ rabbit heart experiments.  The ventricles in each respective 
group were exposed to regional ischemia (open boxes) with or without pre-emptive C1-C2 spinal 
cord stimulation (SCS: filled boxes).  The control group (Protocol 1) consisted of 30 min. of left 
coronary artery occlusion (CAO) followed by a 3-hr reperfusion period.  A similar 30 min. CAO and 
3 hr reperfusion stress was utilized to evaluate all neuromodulation treatments (protocols 2 and 3).  
For pre-emptive SCS, SCS was delivered at frequencies of 50 Hz, 200μs and 90% motor threshold.  
For protocols 1 and 2, the arrow indicates the time when pretreatment with the vehicle (control), 
adrenoceptor blocking agents (prazosin, yohimbine or atenolol) or the muscarinic blocking agent 
atropine occurred.  For protocols 1 and 3, X indicates the time of dorsal column transection at the 
C6 spinal segment (C6 DCNx) or bilateral transection of the cervical vagosympathetic trunk 
(vagotomy).  Specific subsets for protocols 1 (a to d) and 3 (a and b) are indicated on the left.  
Protocol 2 has 5 subsets, as determined by indicated vehicle or drug injection. 
 
Animals in protocol 1 (n = 40) were subjected to 30 min. of regional ventricular ischemia 
followed by a 3-hr reperfusion period. Nine of these animals were in the control coronary occlusion 
group (protocol 1a: sham SCS), 9 animals were pretreated with atropine (0.2mg/kg, iv) 30 min. prior 
to the onset of regional ischemia (protocol 1b). This dose of atropine was sufficient to block the 
bradycardic responses to vagal stimulation.  Eleven animals underwent bilateral transection of the 
dorsal columns at the C6 spinal level 1 hour prior to the onset of regional ischemia (protocol 1c).  
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Selective transection of C6 dorsal columns was confirmed post-mortem. Eleven animals had their 
cervical vagi transected 1 hour prior to the onset of regional ischemia (protocol 1d). 
Pre-emptive electrical neuromodulation. Animals in this part of the study (protocols 2-3) were 
subdivided into seven separate groups. Each group was subjected to 46 min. of SCS initiated 15 min. 
prior to the onset of the 30 min. coronary artery occlusion and terminated 1 min. after release of the 
coronary artery occlusion. The ischemic period was followed by a 3-hr reperfusion period. The 
duration and time point for the onset of pre-emptive SCS applied to upper cervical segments of the 
spinal cord were based upon its effectiveness to reduce infarct size when delivered to the high 
thoracic cord (Southerland et al., 2007). 
Animals in protocol 2 (n = 94) were subjected to 46 min. of C1-C2 SCS, as described above. 
Fifty-four of these animals underwent C1-C2 SCS with vehicle control, run in a blinded fashion with 
each of the protocols using selective autonomic receptor blockade.  To determine whether 
adrenergic or muscarinic receptor blockade affected pre-emptive C1-C2 SCS-induced 
cardioprotection, 40 additional animals were subjected to protocol 2 15 min. after either the α1-
adrenoceptor blocking agent prazosin (0.15mg/kg iv; n = 11), the α2-adrenoceptor blocking agent 
yohimbine (1mg/kg iv, n = 12), the β1-adrenoceptor blocking agent atenolol (2mg/kg iv; n = 8), or 
the muscarinic receptor blocking agent atropine (0.2mg/kg, iv; n = 9) was administered.  The 
prazosin dose was selected because of its effectiveness in blocking the hypertensive response to 
intravenous injections of phenylephrine (100 μm/1 ml).  The dose of atenolol blocked the 
tachycardiac response to intravenous isoproterenol (100 μm/1 ml).  The dose of yohimbine was 
selected according to its effectiveness in stabilizing neuronal processing within the intrinsic cardiac 
nervous system (Richer et al., 2008).  The dose of atropine was sufficient to block any bradycardia 
responses elicited by vagal stimulation.   
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Protocol 3 (n=31) evaluated the potential contributions of intersegmental propriospinal and 
supra-spinal/parasympathetic interconnections in mediating the cardioprotection to C1-C2 SCS.  To 
determine whether C1-C2 SCS effects on myocyte cell death and electrical stability involved 
intersegmental spinal cord connections, we subjected 15 animals to bilateral transection of the dorsal 
columns at C6 (protocol 3a) 1 hr prior to the pre-emptive SCS-coronary artery occlusion stress. 
Selective transection of C6 dorsal columns was confirmed post-mortem.  To determine whether C1-
C2 SCS mediated effects on cardiac viability and electrical stability involved supraspinal pathways, 
reflected back to the heart via the parasympathetic efferent pathways, 16 animals in protocol 3b were 
subjected to bilateral cervical vagotomy 1 hr prior to the SCS-coronary artery occlusion stress.  
 Infarct measurement.  At the end of each experiment, the hearts were rapidly excised, mounted 
on a modified Langendorff apparatus, and perfused with 0.9% saline at 37˚C to remove blood from 
the coronary circulation. Following re-occlusion of the coronary artery that had been occluded 
previously, 2- to 9-μm fluorescent polymer microspheres (Duke Scientific, Palo Alto, CA) were 
injected into the aortic perfusion fluid to demarcate the ventricular region at risk. After removing 
both atria, the rest of the heart was weighed and then frozen at -20˚C. The heart was then cut into 2-
mm-thick slices parallel to the atrioventricular groove. Tissue slices were incubated for 20 min. at 
37˚C in 1% triphenyltetrazolium chloride (TTC) and sodium phosphate buffer (pH 7.4). Tissue 
slices were then placed in 10% formalin to improve the contrast between stained and unstained 
tissue. Areas of infarction (TTC negative), risk zone (negative fluorescence under UV light), and 
non-risk zone (positive fluorescence under UV light) were traced onto plastic overlays. These areas 
were measured using computer-assisted planimetry (Image Research). Infarct and risk zones were 
calculated by multiplying each area by tissue thickness and their products summed. Infarct size is 
expressed as a percentage of risk zone.  
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Immunohistochemistry.  A total of 24 animals were used for this section of the study.  Following 
the 3 hr reperfusion, animals were given a large dose of pentobarbital and then perfused 
transcardially with 2 L of normal saline followed by 2 L of 4% paraformaldehyde in phosphate 
buffered saline (PBS), pH 7.4.  The T2 spinal cord (identified by placing a small dot of Pontamine 
blue dye on the dorsal surface of the C8 spinal cord prior to its removal) was excised and postfixed 
as described previously (Hua et al., 2004).  Consecutive 50 µm sections were cut with a cryostat 
(Leica Microsystems Inc., Bannockburn, IL) at -20oC and placed immediately into wells of 
polypropylene plates containing PBS.  Sections were processed for the presence of c-Fos 
immunoreactivity as described previously (Hua et al., 2004).  Briefly, tissues were rinsed in PBS for 
15 min. and then permeabilized in PBS containing normal donkey serum (NDS; Millipore, Billerica, 
MA) and Triton-X-100 (Sigma) for 20 min.  The sections were then treated with H2O2 (Fisher, 
Pittsburgh, PA) to quench endogenous peroxidase activity.  The sections were rinsed with PBS and 
permeabilized again.  The sections were then incubated in a 10% NDS blocking solution.  Following 
blocking, the sections were incubated in c-Fos antibody from goat (1:15000 in PBS; Cat. # sc-52-G, 
Santa Cruz Biotechnology, Santa Cruz, CA) for 48 hrs at 4oC with constant gentle shaking.  
Following the completion of this incubation, the sections were rinsed and permeabilized followed by 
incubation in biotinylated donkey anti-goat IgG secondary antibodies (1:200, Cat. # 708-065-003, 
Jackson Immunoresearch, West Grove, PA) for 2.5 hrs at room temperature.  The sections were 
rinsed and permeabilized and incubated in ABC solution (1:100, Cat. # PK-4000, Vector Labs, 
Burlingame, CA) for 1 hr at room temperature with constant gentle shaking.  Following incubation 
with ABC solution, the sections were rinsed three times in Tris buffer for 15 min. each.  Following 
these rinses, fos was visualized by incubation in a solution of 10 mg 3’,3’-diaminobenzidine with 7 
µL of 30% H2O2 in Tris buffer.  The reaction was stopped after 4.5 min by transfer of the sections 
to Tris buffer.  The sections were mounted on chrome-alum gelatin coated slides and dehydrated 
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through successive ethanol washes followed by a wash in xylene.  The slides were coverslipped using 
Permount mounting medium (Fisher, Pittsburgh, PA). 
Localization of c-fos immunoreactivity was evaluated using bright-field microscopy using an 
Olympus BH2 microscope.  Quantification of Fos-positive cells in the T2 dorsal horn (Laminae I-V) 
was performed by counting dark brown nuclei in a 200 µm2 area of each animal.  Data were then 
grouped and averaged for each experimental category.  The number of immunoreactive cells in the 
dorsal horn was expressed as cells per square micrometers.   
 Statistical analysis. All data are presented as means (±SD). SigmaStat 3.1 (Systat Software) with 
two-way analysis of variance with post hoc comparisons (Holm-Sidak test) was used to test for 
interactions between SCS and neural ablation (C6 dorsal column transaction or cervical vagotomy) 
and for interactions between SCS and cervical vagotomy versus atropine blockade for modulation of 
infarct size.  One-way analysis of variance with post hoc comparisons (Holm-Sidak test) was used 
for hemodynamic data and for effects of selective adrenergic blockade on infarct size. A significance 
of P < 0.05 was used. Summary data for Fos-positive cells were compared using a two-way ANOVA 
with the Holm-Sidak test for pair-wise comparisons (significance at p<0.05).   
 
RESULTS 
 Hemodynamic variables.  Table 1 summarizes heart rate and blood pressure changes identified 
in each of the four non-SCS experimental groups.  For sham SCS control, dorsal column transection 
control and cervical vagotomy control groups, heart rate was no different during baseline, coronary 
artery occlusion or reperfusion.  For the atropine control group (without C1-C2 SCS), heart rate 
decreased from baseline only in the later stages of reperfusion.  Baseline blood pressures were 
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similar in all four groups of animals.  During coronary artery occlusion, blood pressure was 
significantly decreased from baseline for all groups except vehicle control.  For all four groups, 
blood pressure was decreased significantly from baseline at 1 hour reperfusion. 
 
Table 2 summarizes heart rate and blood pressure for animals with pre-emptive C1-C2 SCS 
with selective autonomic receptor blockade.  For the vehicle-treated group, there were minor 
increases in heart rate associated with C1-C2 SCS and during the subsequent addition of the cardiac 
ischemic stress. In the vehicle control group, blood pressure was reduced significantly from post-
“block” baseline values during coronary artery occlusion and reperfusion.  For selective autonomic 
blockade, pretreatment with prazosin reduced basal mean blood pressure, which was sustained 
throughout the succeeding observation periods.  Pretreatment with atenolol reduced heart rate 
significantly and pretreatment with atropine increased heart rate significantly; these changes were 
sustained throughout the subsequent observation periods.  With the exception of the prazosin 
group, blood pressure decreased during coronary artery occlusion and reperfusion. 
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 Heart rate was minimally affected from baseline values during C1-C2 SCS (Tables 2 and 3).  
Neither was it different during coronary artery occlusion or reperfusion in animals undergoing either 
C6 dorsal column transection or cervical vagotomy (Table 3). Within group comparisons indicate 
that C1-C2 SCS by itself had no significant effect on heart rate or blood pressure.  In all groups, 
blood pressure declined slightly from baseline during the C1-C2 SCS + coronary occlusion, with 
significant reductions from baseline occurring during reperfusion in all three groups (Table 3). 
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Effects of C1-C2 SCS on Infarct size. Body weight and left ventricular risk zones were similar in 
all experimental groups (data not shown). Figure 2 summarizes infarct sizes (expressed as a 
percentage of the zone at risk) quantified in rabbits with intact neuroaxis (cord intact) that were 
subjected to 30-min. periods of regional ischemia in the absence of SCS (Sham SCS) vs. those with 
pre-emptive C1-C2 SCS.  These data were compared to data obtained from similar groups following 
C6 dorsal column transection 1 hr prior to the onset of SCS-coronary artery occlusion (Protocols 1-
3 in Figure 1). There was a significant change in infarct size when comparing different cord status 
(intact versus C6 dorsal column transaction) vs. the absence or presence of SCS (p=0.036) with cord 
status. 
Figure 2. Infarct size (percentage of 
risk zone) for sham SCS rabbits 
without (cord intact) and with C6 
dorsal column transection compared 
to rabbits with pre-emptive C1-C2 
SCS without (cord intact) and with 
C6 dorsal column transection.  For 
each group, individual animals are 
shown along with mean ± SD data 
for each group (open triangle and 
vertical bar).  # p<0.05 for 
innervations state (cord intact versus 
C6 dorsal column transection), 
without (sham) and with pre-emptive 
C1-C2 SCS.  * p<0.05 for SCS 
factor, intact versus C6 dorsal 
column transection. 
In sham animals, ventricular infarct size averaged 43.8 + 6.9% of tissue volume.  This index 
was unaffected by prior C6 dorsal column transection (47.6 ± 14.7%; Fig. 2, column 2).  With the 
spinal cord intact, pre-emptive C1-C2 SCS decreased infarct size to 25.2 + 10.7% (Fig. 2, column 3; 
significant reduction compared to Sham SCS controls). The efficacy of pre-emptive C1-C2 SCS to 
reduce infarct size in response to the 30 min. ischemic stress was eliminated after C6 dorsal column 
transection (Fig. 2, right hand columns infarct size = 42.8 + 9.4%). The ability for pre-emptive C1-
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C2 SCS to reduce infarct size was also eliminated by pretreatment with prazosin (40.0 + 9.4%), 
atenolol (40.2 + 11.1%), or yohimbine (36.8 + 10.3%) (c.f., Fig. 3).  In total, these data indicate the 
ability of pre-emptive C1-C2 SCS to modify sympathetic efferent function via intersegmental 
projections to the thoracic cord. 
Figure 3. Infarct size 
(percentage of risk zone) for 
sham controls compared to 
rabbits with pre-emptive C1-
C2 SCS with intact neuroaxis 
(vehicle) or following 
selective adrenergic receptor 
blockade with α1 (prazosin), 
β1 (atenolol) or α2 
(yohimbine) pretreatment 
(c.f. Fig. 1, protocol 2).  For 
each group, data for 
individual animals are shown 
along with mean ± SD data 
for each group (open triangle 
and vertical bar). * p<0.05 
from all other groups. 
Neither atropine nor cervical vagotomy alone (c.f., in the absence of SCS) affected infarct 
size induced by CAO/ 3 hr reperfusion (Fig. 4, c.f., middle columns of both groups).  Moreover, the 
capacity for pre-emptive C1-C2 SCS to reduce infarct size was unaffected by cervical vagotomy (23.6 
+ 11.1%) compared to vehicle control (25.2 + 10.7%) (Fig. 4).  In contrast, pretreatment with 
atropine 15 min. prior to the onset of pre-emptive SCS (protocol 2) eliminated its infarct reducing 
effects (51.6 + 8.6%). 
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Figure 4. Infarct size (percentage of 
risk zone) in sham controls compared 
to that of rabbits pretreated with the 
muscarinic blocker atropine or cervical 
vagotomy, as compared to animals 
exposed to pre-emptive C1-C2 SCS 
with 1) intact neuraxis (control SCS), 2) 
following cervical vagotomy, or 3) 
muscarinic receptor blockade 
(atropine).  For each group, individual 
animal data are shown along with mean 
± SD data for each group (closed 
diamond and vertical bar). # p<0.05 
for treatment (none, cervical vagotomy 
or atropine) with and without pre-
emptive C1-C2 SCS.  * p<0.05 (with 
pre-emptive C1-C2 SCS) for atropine pre-treatment versus control or cervical vagotomy. 
Effects of C1-C2 SCS on ventricular arrhythmogenic potential.  Ventricular fibrillation secondary to 
myocardial ischemia occurred in 22% of control animals (sham SCS) with 11% experiencing sudden 
cardiac death (SCD) (Table 4).  Across all groups, VF occurred preferentially in the first ½ of the 
ischemic insult with no stratification with respect to those that showed spontaneous conversion 
back to sinus rhythm versus those that did not recover, e.g. SCD.  Incidence of CAO-induced VF 
increased to 36% in animals with prior vagotomy or C6 dorsal column transection, with incidence of 
SCD of 18% for both groups (Table 4).  Pretreatment with atropine showed similar responses to 
control. 
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In animals with C1-C2 SCS, pretreatment with cholinergic or adrenergic antagonists, along 
with selective neuroablation, modified the incidence of CAO-induced VF and subsequent events of 
SCD (Table 4).  C1-C2 SCS by itself did not alter the incidence of either VF or SCD.  Prior C6 
dorsal column transection however, increased the lethality of CAO.  In contradistinction to sham 
SCS animals, prior cervical vagotomy completely eliminated the incidence of CAO-induced VF.  
Such was not case with atropine pretreatment where CAO applied during SCS resulted in a 33% 
CAO-induced VF with 11% subsequent SCD.   Pretreatment with alpha adrenergic blockade was 
associated with substantial increases in events, especially following α2 blockade, with the incidence of 
CAO-induced VF increasing to 92%; 50% of such animals having SCD.  In contrast, prior treatment 
with the β1 adrenergic selective blockade (atenolol) completely eliminated CAO-induced VF.  These 
data point to the dynamic interactions between adrenergic and cholinergic control of cardiac 
electrical stability in ischemic stress. 
Effects of C1-C2 SCS on thoracic dorsal horn activity.  The effects of CAO on cFos-
immunoreactivity in the dorsal horns (Laminae I-V) of the T2 spinal cord were examined to 
determine how spinal cord neurons transduce the effect of CAO in the absence and presence of C1-
C2 SCS (Figure 5).  Coronary artery occlusion (CAO) increased activation of the laminae I-V 
neurons in the high thoracic spinal cord.  CAO increased this index from 7.19±3.50 Fos-positive 
cells per 200 µm2 in control states to 19.36±5.46 cells per 200 µm2.  C1-C2 SCS alone increased this 
activation index in dorsal horn neurons of the high thoracic spinal cord to a lesser degree when 
compared to control states (9.73±4.82 cells per 200 µm2).  In the presence of C1-C2 SCS, CAO-
induced activation of dorsal horn neurons was reduced when compared to animals subjected to 
CAO alone (3.18±1.83 cells per 200 µm2; p=0.028). 
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Figure 5.  Activation of neurons in the 
thoracic spinal cord in response to 
ischemia.  C-fos expression was 
measured in dorsal horns (laminae I-V) 
of the upper thoracic spinal cord.  
Coronary artery occlusion (CAO) caused 
an increase in the activation of spinal 
neurons.  Following SCS, this increase 
was lessened indicating reduction in 
cardiac afferent neuronal activation.  
SCS applied prior to and during CAO 
caused a greater (significant) reduction 
in dorsal horn spinal neuronal activation.  
* indicates p<0.05 using two-way 
ANOVA with the Holm-Sidak post hoc comparison. 
 
Discussion 
 This study demonstrates for the first time that pre-emptive electrical neuromodulation 
therapy applied to the cranial cervical spinal cord reduces the size of infarcts induced by transient 
myocardial ischemia.  It further indicates that disruption of intersegmental communication from C1-
C2 to T1-T4 cord neurons, by transection of the C6 dorsal column, prevents the infarct reducing 
effect of C1-C2 electrical stimulation.  Thus, a necessary difference in control is exerted by thoracic 
cord neurons (Foreman et al., 2004; Foreman et al., 2000; Wu et al., 2008) versus cervical neurons, 
given the potential of high cervical cord neurons to modify not only thoracic cardiac efferent 
adrenergic neuronal outputs, but also vagal neuronal outflows to modulate infarct size in response to 
the regional ischemia (Fig. 3).   
Although cervical vagotomy did not affect the capacity of pre-emptive high cervical SCS to 
modify infarct size, this does not preclude some involvement of peripheral cardiac cholinergic 
neurons in these events since atropinization completely abolished the capacity of C1-C2 SCS to 
reduce infarct size.  Cervical vagotomy decentralizes parasympathetic inputs to the intrinsic cardiac 
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nervous system (ICN) but still allows for spontaneous neuronal activity and intracardiac reflex 
function (Ardell et al., 1991), whereas atropine interferes with both end-organ and neuronal 
processing within the ICN (Armour, 2008).  In other words, high cervical SCS affects ventricular 
electrical stability via both sympathetic and parasympathetic efferent neurons.   
There appears to be concurrent influences of alpha- and beta-adrenoceptor neurons in such 
events since blockade of either receptor subgroup elicited diametrically opposed responses on the 
incidence of sudden cardiac death.  While β1-adrenoceptor blockade mitigated the potential for 
sudden cardiac death, α1- and α2-adrenoceptor blockade enhanced (doubled or tripled, respectively) 
that potential.  In contrast, following cervical vagotomy while coronary artery occlusion alone was 
associated with an increased incidence of sudden cardiac death, concurrent high cervical SCS (post 
vagotomy) completely abolished ventricular fibrillation initiated during transient myocardial 
ischemia.   
 With regards to neural responses to cardiac stress, electrical stimulation of the C1-C2 dorsal 
column region is known to decrease the activity of spinothalamic tract neurons receiving cardiac 
nociceptive sensitive inputs (Chandler et al., 1993; Foreman et al., 2004).  It also decreases myocardial 
ischemia evoked dorsal horn neuronal activation (Ding et al., 2008a; Ding et al., 2008b) and 
substance P release from ischemia sensitive cardiac afferent neurons, while recruiting thoracic spinal 
sympathetic neurons (Ding et al., 2008a; Ding et al., 2008b).   
Cranial cervical cord information is transmitted to the lower segments of the spinal cord via 
the dorsal columns, propriospinal pathways and/or supraspinal loops.  C1-C2 SCS does not activate 
supraspinal neurons, including those in brainstem nucleus tractus solitaries (Ding et al., 2008a; Ding 
et al., 2008b; Qin et al., 2007).  In fact, C1-C2 SCS or chemically-activated C1-C2 propriospinal 
neurons suppress the responses of upper thoracic spinal neurons to noxious cardiac afferent input 
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(Qin et al., 2004; Qin et al., 2008).  C1-C2 SCS also inhibits substance P release from activated 
ischemia sensitive cardiac afferent neurons (Ding et al., 2008b; Ding et al., 2008a).  Thus, caudal 
cervical dorsal column transection mitigates cranial cervical-mediated processing of noxious visceral 
afferent inputs (Qin et al., 2007).  These results are in accord with the finding that C6 dorsal columns 
transection mitigates C1-C2 SCS ventricular infarct size reduction secondary to transient myocardial 
ischemia.  Such data indicate that spinal cord propriospinal descending projections or antidromic 
activation of ascending fibers in the dorsal column influence high cervical inputs to the thoracic 
spinal cord neurons. 
Cervical cord neuromodulation of ischemia-induced myocardial infarction.  Adrenergic receptors 
modulate both cardiomyocytes and neurons that regulate them (Armour, 2008; Ardell, 2004).  Thus, 
infarct size can be influenced via α-receptor coupled PKC pathways as well as β-adenoreceptor 
coupled PKA and p38 MAPK pathways (Yellon & Downey, 2003; Tsuchida et al., 1994; Sanada & 
Kitakaze, 2004).  In fact, high thoracic SCS activates cardiomyocyte PKC (Southerland et al., 2007).  
Furthermore, the capacity of C1-C2 SCS to reduce infarct size can be eliminated by α or β1 
adrenergic blockade. In other words, intersegmental spinal cord interactions may impart 
cardioprotection, in part, via cardiac adrenergic efferent neurons.   
In the current study, cervical vagotomy did not change C1-C2 SCS-mediated reduction in 
infarct size while atropine eliminated it.  Cholinergic receptors influence cardiomyocytes directly and 
indirectly via the cardiac neuroaxis (Armour, 2008; Ardell, 2004).  The minimal impact of vagotomy 
on C1-C2 SCS-induced infarct size reduction may reflect at least three factors: 1) the lack of 
contribution of C1-C2 SCS evoked activity on supraspinal projections to the nucleus tractus 
solitaries (Ding et al., 2008a; Ding et al., 2008b), thereby minimally effecting parasympathetic efferent 
neuronal outflow to the heart; 2) maintenance of parasympathetic efferent neuronal outflow changes 
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from the intrinsic cardiac nervous system post-cervical vagotomy (Ardell et al., 1991; Huang et al., 
1993; Murphy et al., 2000); and 3) the function of intrathoracic reflexes, including those on the heart 
(Foreman et al., 2000; Armour et al., 2002; Ardell et al., 2009).  
Neuromodulation therapy and arrhythmias.   These data provide important insights into putative 
interactions that occur among peripheral and central aspects of cardiac neuroaxis and its impact on 
electrical stability of the ischemic heart.  Pre-emptive thoracic SCS is known to impact afferent 
(Foreman et al., 2004; Chandler et al., 1993; Ding et al., 2008a; Ding et al., 2008b), efferent 
(Southerland et al., 2007; Olgin et al., 2002; Ardell et al., 2009) and local circuit neuronal (Cardinal et 
al., 2006; Armour et al., 2002; Ardell et al., 2009) processing within brainstem, spinal cord, and 
peripheral nodes of the cardiac neuroaxis.  When specific elements of this neuronal hierarchy for 
cardiac control are altered, control of cardiac function may become compromised (Armour, 2008). 
For instance, the increased incidence of myocardial ischemia-induced sudden cardiac death 
identified following C6 dorsal column transection may reflect a loss of descending inhibitory 
restraints on spinal cord sympathoexcitatory reflexes (Ardell et al., 1982).  Correspondingly, the 
increase in myocardial ischemia-induced sudden cardiac death post α2-adrenoceptor blockade may 
be reflective of imbalances in neurotransmitter release secondary to loss of negative feedback on 
neurotransmitter release from autonomic efferent postganglionic neurons (Xu & Adams, 1993; 
Adams & Cuevas, 2004).  With respect to α1-adrenoceptor blockade and a resultant loss of 
background excitation of subpopulations of intrinsic cardiac neurons (Armour, 1997; Ishibashi et al., 
2003; Richer et al., 2008), subsequent reflex activation derived from ischemia-sensitive afferent 
neuronal inputs may asymmetrically modify efferent neuronal outputs such that any arrhythmogenic 
substrate becomes enhanced.   
50 
 
The abolition of myocardial ischemia-induced sudden cardiac death post-vagotomy in the 
presence of high cervical SCS seems to be counter-intuitive to the documented anti-arrhythmogenic 
effects of enhanced parasympathetic efferent neuronal activity (Vanoli et al., 2008; Schwartz, 2001).  
It should be noted that imbalances in cardiac sympathetic and parasympathetic control initiated by 
ischemia can be mitigated by: 1) interrupting parasympathetic preganglionic neuronal inputs (post-
vagotomy) (Huang et al., 1993); and 2) the stabilizing effects of SCS on the intrinsic cardiac nervous 
system (Armour et al., 2002; Foreman et al., 2000).   
Fos expression is an indicator of cellular activation in the spinal cord as manifested, in this 
instance by cardiac afferent neuronal activation secondary to cardiac ischemia transduction (Hua et 
al., 2004; Ding et al., 2008a).  Ischemia activates populations of the cardiac afferent neurons, as 
indicated by increased Fos expression in the high thoracic spinal cord dorsal horn, specifically 
laminae I-V, as reported in other studies (Hua et al., 2004).  Such afferent neuronal activation to the 
spinal cord, secondary to myocardial ischemia transduction, also occurs following application of 
noxious stimuli to afferent neuronal inputs to lower thoracic and lumbar spine (Qin et al., 2007).  
Myocardial ischemia activation of cardiac afferent neuronal inputs to the spinal cord and higher 
centers (Hua et al., 2004; Ding et al., 2008a) may initiate deleterious reflexes (Hua et al., 2004; Ding et 
al., 2008a), thereby indirectly modifying cardiac function.  Any ability to moderate such reflexes may 
moderate such adverse effects. 
Neuromodulation of the spinal cord at a level higher (C1-C2 SCS) than the incoming cardiac 
sympathetic afferent neuronal inputs (T1-T5) demonstrates that intersegmental interactions that 
sub-serve reflex processing can occur within and between various levels of the spinal cord.  Thus, 
these data support the thesis that high cervical spinal segments of the spinal cord may not only act as 
a coordinating center for visceral organ afferent inputs traveling centrally but also display a capacity 
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to modify sympathetic efferent control of visceral organs (Qin et al., 2007; Ding et al., 2008b; Ding et 
al., 2008a). 
Perspectives and significance 
High cervical SCS stabilizes reflex processing within the cardiac neuroaxis to reduce infarct 
size and the potential for ischemia-induced sudden cardiac death, doing so via modulating not only 
efferent adrenergic outflow, but also cholinergic outflow to the heart (Fig. 6).  These data also 
indicate that cervical SCS neuromodulation therapy targets multiple nodes of the cardiac neuroaxis, 
namely both sympathetic and parasympathetic efferent outflows to the heart.  That C6 dorsal 
column transection and cervical vagotomy exerted differing effects on myocyte viability post-
ischemia or even evoked sudden cardiac death point to the importance of understanding the 
multiple interactions existing within the various nodes of the cardiac neuroaxis.  This was made 
evident by the fact that β-adrenergic blockade, while reducing the risk for myocardial ischemia-
induced sudden cardiac death, obtunded any infarct size reduction capability of SCS.  It is only by 
understanding the interactions that occur among peripheral and central nodes of the cardiac 
neuroaxis that appropriate therapies targeting select neuroaxis components can evolve. 
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Figure 6.  Schematic of proposed interactions that occur within and among intrathoracic autonomic 
neurons and between them and central neurons.  Intrinsic cardiac ganglia possess afferent neurons, 
sympathetic (Sympath) and parasympathetic (Parasym) efferent neurons and interconnecting local 
circuit neurons (LCN).  Extracardiac intrathoracic ganglia contain afferent neurons, local circuit 
neurons and sympathetic efferent neurons.  Neurons in these intrinsic cardiac and extracardiac 
networks form separate and distinct nested feedback loops that act in concert with CNS feedback 
loops involving the spinal cord and medulla to coordinate regional cardiac function on a beat-to-
beat basis.  Symbols: Aff., afferent; DRG, dorsal root ganglia; Gs, stimulatory guanine nucleotide 
binding protein; Gi, inhibitory guanine nucleotide binding protein; AC, adenylate cyclase; beta-1 
adrenergic receptor; M2- muscarinic receptor. 
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Abstract 
 This study evaluated whether electrical neuromodulation therapy applied to the rostral 
thoracic spinal cord affects the capacity of cardiac first order afferent neurons to transduce 
myocardial ischemia.  We recorded the transduction characteristics of left ventricular primary 
afferent neuronal somata in nodose and dorsal root ganglia (DRG) in situ in response to exposing 
their sensory neurite fields to chemical stimuli versus regional ventricular ischemia (transient left 
anterior descending [LAD] coronary artery occlusion).  Epicardially applied veratridine activated 
both sensory populations, as did transient ventricular ischemia.  After 20 min. of spinal cord 
stimulation (SCS: 50 Hz, 200 ms duration, 90% motor threshold applied to dorsal columns of T1-T3 
spinal segments) the ischemia-induced depression of left ventricular chamber dp/dt was mitigated.  
SCS likewise attenuated the capacity of both sensory populations to transduce local ischemia.  Yet, 
SCS did not directly (antidromically) activate somata of either population.  It is concluded that while 
SCS does attenuate ischemia-induced enhancement of nodose and dorsal root ganglion ventricular 
sensory neurons, this is reflective of an altered milieu surrounding their neurites rather than direct 
(antidromic) somata effects.  These data further imply that while such neuromodulation therapy can 
alter cardiac afferent response to transient MI, such alterations are secondary to changes in the 
transduction of cardiac milieu rather than suppression of the afferents’ capacity to transduce that 
milieu.  
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Introduction 
 A pressing issue with respect to spinal cord stimulation therapy (SCS) in the treatment of 
myocardial ischemia (MI) remains whether if such therapy obtunds the capacity of cardiac primary 
afferent neurons to transduce MI (Foreman and others 2004; Mannheimer and others 2002).  If 
blunting of the transduction capabilities of the cardiac neuroaxis to transduce an ischemic event 
does indeed occur, that might negate the clinical usefulness of SCS because the patient would no 
longer become aware of critical ischemic episodes (Armour 2008).  Cardiac afferent neurons, 
distributed throughout nodose and cranial thoracic dorsal root ganglia (DRG), transduce a 
constantly changing cardiac mechanical and chemical milieu (Armour 1999; 2004).  The neurites of 
cardiac afferent neurons are activated by a number of chemicals, including those known to be 
released from the ischemic myocardium: c.f., adenosine and peptides such as bradykinin and 
substance P (Armour and Kember 2004).  It is well recognized that nodose and DRG cardiac 
afferent neurons exert major influences via the cardiac neuroaxis on regional cardiac dynamics via 
reflex modification of both sympathetic and parasympathetic efferent outflows (Ardell 2004; 
Armour 1999; 2004). 
 Neuromodulation applied to select nodes of the cardiac neuroaxis (e.g. SCS applied at T1-T3 
spinal levels) is known to mitigate excessive MI-induced reflex activation of extracardiac (Ardell and 
others 2009) and intrinsic cardiac neurons (Foreman and others 2000).  SCS does so without 
interrupting direct autonomic efferent projections to the heart (Cardinal and others 2006).  It has 
been proposed that SCS modulates sensory transduction of the ischemic myocardium to neurons in 
the thoracic spinal cord dorsal horn (Qin and others 2008).  SCS has been demonstrated to 
modulate the response of second order neurons within the spinal cord to ischemia (Qin and others 
2008).  Conversely, recent evidence has suggested that SCS directly activates DRG afferent neurons 
62 
 
to increase their release of neurotransmitters into peripheral tissues from their sensory neurites, 
imposing an efferent function on afferent neurons (Linderoth and others 1994).  In fact, it has been 
proposed that this afferent/efferent function could be a primary mechanism whereby SCS exerts its 
clinical benefits to the cardiac patient (Linderoth and others 1994). However to date, the effects of 
SCS on first order cardiac afferent neurons has not been assessed. 
 To evaluate whether such SCS neuromodulation therapy does indeed blunt a patient’s 
capacity to sense an ischemic event, we sought to determine: 1) whether SCS alters the capacity of 
first order cardiac sensory neurons to transduce MI and, if that is the case, 2) whether that occurs via 
direct antidromic modification of first order afferent neuronal somata or 3) indirectly by altering the 
milieu surrounding their cardiac sensory neurites. 
 
Materials and Methods 
 Animal preparation:  Mongrel dogs (n=41; either sex), weighing 17.1-28.0 kg, were used in this 
study.  All experiments were performed in accordance with the guidelines for animal 
experimentation described in the “Guiding Principles for Research Involving Animal and Human 
Beings” (Society 2002).  The Institutional Animal Care and Use Committee of the East Tennessee 
State University approved these experiments. 
 Animals were pre-medicated with sodium thiopental (25 mg/kg, i.v., supplemented as 
needed), intubated and maintained under positive-pressure ventilation.  Isoflurane (2%) was used as 
the anesthetic agent during surgery.  Following surgery, the anesthesia was switched to α-chloralose 
(75 mg/kg i.v. bolus, with repeat doses of 12.5 mg/kg i.v., as required).  Heart rate and blood 
pressure were continuously monitored with depth of anesthesia determined by monitoring corneal 
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reflex, jaw tone, and hemodynamic parameters.  Body temperature was maintained via a circulating 
water heating pad (Gaymar T/Pump, Gaymar Industries Inc., Orchard Park, NY). 
 The left femoral artery and vein were catheterized to monitor blood pressure and deliver 
anesthetic agents throughout the experiment.  The right femoral artery was catheterized and a 
Mikro-Tip Pressure Transducer Catheter (Millar Instruments, Houston, TX) was advanced into the 
left ventricular (LV) chamber.  Heart rate was monitored via a Lead II electrocardiogram.  These 
indices, along with concurrent afferent neuronal activity (see below), were digitalized (Power 1401, 
Cambridge Electronic Design, Cambridge, England), stored and analyzed offline by the Spike2 
(Cambridge Electronic Design, Cambridge, England). 
 Spinal cord stimulation (SCS):  Two different protocols for SCS electrode placement were used, 
depending on the site of afferent recording.  With respect to experiments for recording nodose 
activity, animals were first placed in the prone position and the spinal epidural space was penetrated 
percutaneously with a Touhy needle through a small skin incision in the T6 spinal level.  An eight-
pole lead (Octrode, Advanced Neuromodulation Systems, Plano, TX) was advanced rostrally in the 
epidural space to the T1-T3 spinal cord level.  The tip of the lead was positioned slightly to the left of 
midline under fluoroscopy.  Consistent with current clinical practice (Augustinsson and others 
1995), the rostral pole was positioned at T1 and the caudal pole was positioned at T3 level.  With 
respect to DRG neuronal activity recordings, a laminectomy was performed removing the dorsal 
spinal processes of the C8-T6 vertebrae and the eight-pole lead was laid directly on the dorsal aspect 
of the T1-T3 spinal cord.  In both cases, proper electrode placement was determined by delivering 
electrical current to the spinal cord dorsal horn via the rostral (cathode) and caudal (anode) poles of 
the electrode using a PSIU6 constant current isolation unit (Grass Instruments, Quincy, MA) 
connected to a Grass S88 stimulator (Grass Instruments, Quincy, MA).  Motor threshold (MT) 
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intensity was determined as the lowest current that induced muscle contractions in the proximal 
forepaw and shoulder.  For nodose ganglion recordings, following SCS electrode implantation the 
animals were rotated to the supine position, with MT being rechecked in this position.  In each 
experimental protocol, SCS was delivered for 20 min. at 50 Hz, 200 µs duration and at a current 
intensity of 90% MT (range 0.25-2.8 mA, mean 0.98±0.19 mA).  MT was checked periodically 
during the experiments.  MT did not vary significantly from initial levels throughout each 
experiment. 
 Afferent neuronal activity recording:  Activity generated by neuronal somata in the nodose ganglia 
of 20 animals vs. neuronal somata in the DRGs in 21 animals was recorded in situ, using methods as 
reported previously (Gagliardi and others 1988).  Briefly, for nodose ganglion recordings, the 
animals were placed in the prone position and an incision was made in the ventral neck to expose 
the nodose ganglia.  The tissue surrounding the nodose ganglia was left intact to stabilize it during 
prolonged recording of the activity generated by neuronal somata therein.  With respect to recording 
DRG somata activity, animals were placed in a supine position and after laminectomy (C8-T6) the 
T1-T4 DRG ganglia were exposed. 
 For either DRG or nodose neurons, a tungsten microelectrode (250 µm diameter and 
exposed tip of 1 µm; impedance of 9-11 MΩ at 1000 Hz), mounted on a micromanipulator, was 
lowered into respective ganglia using a microdrive.  Each ganglion was explored and electrical signals 
so derived were led into a differential preamplifier (BMA-831, CWE Inc., Ardmore, PA) with a high 
impedance head stage (band width set at 300 Hz to 10 kHz).  Signals were further amplified by a 
battery-driven pre-amplifier (5113 Pre-Amp, Signal Recovery, Oak Ridge, TN) (band width 100 Hz 
to 2 kHz).  Amplified neuronal signals, together with recorded cardiovascular indices, were digitized 
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(Cambridge Electronics Design, power 1401 data acquisition system), stored, and analyzed using the 
Spike 2 software package (Cambridge Electronics Design).   
 Neuronal activity was identified as action potentials with signal to noise ratios greater than 
3:1.  The activity generated by individual neuronal somata in either the nodose or DRG ganglia was 
identified by the amplitude and configuration (waveform recognition) of these recorded action 
potentials using the Spike 2 program.  Using these techniques and criteria, action potentials 
generated by individual somata and/or dendrites, rather than axons of passage, can be recorded for 
extended periods of time (Gagliardi and others 1988). 
 Protocols employed:  Gauze soaked in solutions of the following chemicals: veratridine (100 
µM), bradykinin (100 µM), adenosine (100 µM), or substance P (10 µM) were first applied to the 
surface of the ventral left ventricle to test whether recorded nodose or DRG soma transduced 
cardiac stimuli.  After waiting 1 min., the chemical-soaked pledge was removed and the pericardium 
flushed with normal saline.  If none of the DRG or nodose ganglion neurons were activated by 
these chemicals, the microelectrode was moved until an active site was identified that consistently 
responded to chemical activation of the LV sensory neurites.  Once such a subset of nodose or 
DRG neurons was identified, the left anterior descending (LAD) coronary artery was occluded for 1 
or 2 min by means of a silk ligature snare placed around that vessel at the level of its first diagonal 
branch.  If coronary artery occlusion (CAO) did not evoke changes in primary afferent activity, the 
electrode was moved to another recording site.  Once a population of LV afferent neurons was 
identified which responded first to chemicals and then to LAD CAO, animals were randomized to 
receive either pre-emptive SCS (50 Hz, 200 µs, 90% MT) for 20 min or sham SCS for 20 min and 
the LAD CAO stress repeated.  In a separate group of 3 animals with DRG recordings, the dorsal 
roots were sectioned between identified ganglia and the spinal cord; all other DRG were left intact.  
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Thereafter, the capacity of neuronal somata therein to transduce myocardial ischemia was studied 
before and after SCS. 
 Suprathreshold SCS: In a subset of animals (n=5), we evaluated the potential of spinal cord 
stimulation to modify identified DRG neural activity antidromically.  A short-acting competitive 
neuromuscular blocker, rocuronium bromide (1 mg/kg; time to onset 2-4 min. with clinical duration 
of action of 20 min. (Sparr and others 2001)), was used to temporarily prevent spinal cord 
electrically induced motor movement.  For these experiments, the frequency of spinal cord 
stimulation ranged from 0.1 to 5 Hz and the voltage employed ranged from motor threshold to 2.5x 
motor threshold.  For these experiments, alpha chloralose (8-12 mg/kg) was temporarily increased 
prior to neuromuscular blockade and maintained at that level during subsequent supra-motor 
threshold stimuli. 
 Data analysis:  Action potentials arising from a nodose or dorsal root ganglion site were 
characterized by means of differences in their amplitudes and configurations, employing waveform 
recognition analysis (Spike2 program).  Neuronal activity changes elicited during each intervention 
were evaluated by comparing activity generated immediately before chemical application or 
occlusion with data obtained during and following (e.g. reperfusion) those interventions.  Average 
activity data are presented as impulses per second.  Antidromic responses to SCS were quantified by 
spike-triggered averages of afferent neuronal activity during the progressive suprathreshold 
stimulation protocols, the spike derived from delivery of electrical pulses to the SCS electrode.  All 
data are expressed as means ± SEM.  SigmaStat 3.1 (Systat software) with 2-way ANOVA with post-
hoc comparisons (Holm-Sidak method) was used to test for differences between groups.  A 
significance of p< 0.05 was used for these data analyses. 
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Results 
 Hemodynamic data:  Since both groups generated similar hemodynamic changes during LAD 
coronary artery occlusion (CAO), CV indices obtained during nodose and DRG studies were 
grouped together.  Before SCS, MI induced a significant increase in heart rate (115±9 to 130±9 
beats/min; p<0.05).  CAO in control states likewise did not significantly change left ventricular 
systolic pressure (140±4 - 134±4 mm Hg; ns) or mean arterial blood pressure (134±6 – 129±6 mm 
Hg; ns).  However, CAO did reduce +LV dp/dt (1999±98 to 1852±96 mmHg/sec; p<0.01) and –
LV dp/dt (-2755±340 to -2159±320 mmHg/sec; p<0.02).  SCS by itself did not change any 
recorded CV variable.  Following SCS, the major change in CAO-induced hemodynamic responses 
was that +LV dp/dt (control: 2037±83 mmHg/s vs. 1976±53 mmHg/s; ns) was significantly altered 
during the ischemic stress.  In contrast, the LV dp/dt depression was maintained with repeated 
occlusions. 
 Dorsal root ganglion afferent neuronal activity:  The activity generated by identified DRG neurons 
increased during epicardial veratridine application (0.4±0.2 to 2.9±0.6 imp/s).  Subsequent ischemic 
challenge evoked a brisk increase in neuronal activity, especially at the transition points between 
normal flow and ischemia (e.g. onset and release).  Fig. 1 demonstrated that the duration of transient 
MI-induced activity exceeds the duration of the ischemic insult.  Overall, LAD CAO increased 
average DRG activity (0.6±0.2 to 2.7±0.8 imp/s; p<0.02) with even greater activity levels observed 
during reperfusion (4.9±2.6 imp/s; p>0.05 from control and ischemic states; c.f., Figs. 1 & 2).  The 
average recovery from peak activity to baseline of the evoked response in DRG activity to a 1 min 
LAD CAO was 207±35 s.  Enhancement of DRG activity in response to repeated LAD CAO (time 
control) remained stable (415 % increase, LAD CAO 1 versus 570% increase, LAD CAO 2).  
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Recovery of evoked responses from peak activity to baseline was likewise maintained in time 
controls (180±49 s for first LAD to 220±135 s for second LAD). 
 
Figure 1:  DRG neuronal activity recorded in response to 1 min. LAD CAO.  LAD CAO increased 
DRG afferent neuronal activity, activity increasing further during reperfusion.  DRG neuronal 
activity was also grouped into 10 second segments to display average rate changes over time (3rd 
trace).  LVP = Left ventricular pressure.  HR = Heart rate.   
 SCS mitigated increases in DRG afferent neuronal activity evoked by LAD CAO (Fig. 2).  
While in control states LAD CAO increased their activity (0.6±0.2 imp/s to 2.7±0.8 imp/s 
(p<0.02)), following SCS the MI-induced stressor no longer changed DRG activity (0.4±0.3 to 
0.5±0.2 imp/s (ns)).  After SCS, the reperfusion phase was also associated with reduced activity 
(0.6±0.4 imp/s).  In the 3 dogs in which the recorded dorsal root ganglia was acutely decentralized 
from the spinal cord, SCS still reduced the LAD CAO-induced activation of the primary cardiac 
afferent neurons within these ganglia (290% increase from baseline of 0.5±0.3 imp/s to 33% 
increase from baseline of 0.3±0.2 imp/s post SCS).  For this experiment, DRG located rostral and 
caudal to the recorded ganglia and all contralateral DRG remained connected to the spinal cord. 
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Figure 2:  Activity 
generated by DRG 
neurons recorded during 
baseline, LAD CAO and 
reperfusion, peak activity 
being achieved during 
reperfusion.  Following 
SCS, the capacity of these 
neurons to transduce 
ventricular ischemia and 
subsequent reperfusion 
was reduced.  * p<0.05 
comparing baseline and 
ischemia data during 
before SCS; + p<0.05 
post-SCS, comparing 
control and ischemia data. 
 Nodose ganglion afferent neuronal activity:  The activity generated by identified nodose ganglion 
afferent neuronal somata increased during LAD CAO from 1.35±0.49 to 2.94±0.87 imp/s 
(p<0.001), maintaining their enhanced state during reperfusion (Fig.3).  Repeat LAD CAO elicited 
similar neuronal responses.   Nodose ganglion afferent neurons that responded to transient 
ventricular ischemia were initially identified by their evoked response to chemical stimuli applied to 
the LV epicardial ventral surface.  Of the 34 ischemic-sensitive afferent neurons evaluated, 44% 
responded to epicardial application of veratridine (0.8±0.2 to 3.5±1.2 imp/s; p<0.05), 44% 
responded to bradykinin (0.7±0.5 to 3.2±1.0 imp/s; p<0.01), 24% to adenosine (0.6±0.1 to 1.3±0.3 
imp/s; p0.01) and 35% to substance P (0.3±0.1 to 1.6±0.6 imp/s; p<0.03). 
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Figure 3:  Activity of 
nodose ganglion afferent 
neurons prior to, during 
and after (reperfusion) 2 
min. of LAD CAO.  
Following SCS (right 
columns) the ability of 
ischemia to activate 
nodose cardiac afferent 
neurons decreased 
significantly.  * p<0.05 
comparing ischemia to 
baseline data in control.; 
+ p<0.05 comparing 
post- to pre-SCS data. 
 
 Following SCS, the capacity of nodose ganglion afferent neurons to transduce regional left 
ventricular ischemia was reduced compared to control states (Fig. 3).  During control states ischemia 
enhanced nodose ganglion neuronal activity from 0.4±0.2 to 0.9±0.2 imp/s (p<0.05).   Following 
SCS, ischemia elicited only minor enhancement of their activity (0.2±0.1 to 0.3±0.1 imp/s; ns) (Fig. 
3).  Similarly, SCS obtunded nodose ganglion neuronal activation during the reperfusion phase 
(0.9±0.3 imp/s versus 0.2±0.1 imp/s; ns).  SCS also truncated the duration of nodose afferent 
neuronal excitation in response to the 1 min ischemic stress (200±28 sec control vs 90±10 sec post 
SCS; p=0.01). 
 DRG activity during supra-threshold SCS:  To determine whether identified dorsal root ganglion 
afferent neuronal somata could be antidromically activated by SCS, their activity was recorded as 
SCS was applied at varying frequencies (0.5, 1 and 5 Hz) at intensities ranging from 90% MT to 2.5x 
MT (Fig. 4).  Spike-triggered averages of DRG activity, based upon delivered SCS pulses, were used 
to quantify the potential for antidromic activation.  No combination of frequencies or intensities of 
stimuli evoked action potentials time-locked to the SCS pulses in identified ventricular afferent 
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neurons indicating no antidromic activation of cardiac-related DRG neurons by SCS parameter sets 
utilized. 
Figure 4:  In intact preparations, stimulation (frequency of 0.5 Hz) of the dorsal spinal cord with 
different current intensities (MT, MT, 1.5x MT, 2x MT, and 2.5x MT) failed to activate identified 
DRG cardiac afferent neurons (bottom trace).  SCS = spinal cord stimulation. DRG activity = 
dorsal root ganglion activity. 
 
Discussion: 
 The results of this study demonstrate that the capacity of first order cardiac afferent neurons 
(nodose and dorsal root ganglia) to transduce an ischemic myocardium is obtunded following 
application of SCS.  Previous work has indicated that SCS can suppress local circuit neurons in 
peripheral ganglia without (Foreman and others 2000) interfering flow-through efferent pathways of 
the sympathetic and parasympathetic nervous systems (Gibbons and others 2011).  SCS likewise 
72 
 
blunts ischemia-induced reflex activation of central and peripheral aspects of the hierarchy for 
cardiac control (Ardell and others 2009; Foreman and others 2000; Qin and others 2008).  This is 
the first demonstration of SCS-mediated suppression of first order cardiac-related afferent inputs 
and these effects are reflected on both DRG and nodose neurons. 
 Previous studies have demonstrated that SCS modulates the responsiveness of ischemia-
sensitive neurons located within the spinal cord related to both pain perception (Krames and 
Foreman 2007; Qin and others 2008) and cardiovascular control (Ding and others 2008a; Ding and 
others 2008b).  The spinothalamic tracts carry nociceptive inputs from cardiac-related DRG neurons 
to higher centers of the central nervous system (Krames and Foreman 2007; Qin and others 2008).  
SCS likewise modulates reflex activation of peripheral aspects of the cardiac nervous system 
(Armour and others 2002; Foreman and others 2000), a response likely related to suppression of 
local circuit neurons (Gibbons and others 2011). 
Cardiac nociceptive inputs project centrally via multiple pathways (Marieb 2004).  Vagal 
cardiac afferent neurons have their soma in nodose ganglia and project to nucleus tractus solitarius 
neurons of the medulla (Marieb 2004)  Dorsal root ganglia neurons project centrally to the dorsal 
horn of the spinal cord and from there second order neurons project to other regions of the spinal 
cord and supraspinal sites (Kuo and others 1984).  As both populations (DRG and nodose) were 
suppressed by SCS, it is unlikely that any suppressor effects can be ascribed to anti-dromic activation 
of either population.  That concept was confirmed by direct recording of the activity generated by 
DRG neurons in the presence of low frequency SCS (c.f., no antidromic activation). 
 Ischemia is known to cause a decrease in myocardial contractility as indicated by a decrease 
in LV dp/dt (Khalil and others 2005).  The transient period of ischemia used in this study was 
sufficient to cause a significant decrease in LV dp/dt.  Following SCS, while basal contractile 
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function was unaffected, transient LAD CAO failed to evoke a decrease in LV dp/dt.  This finding 
indicates that SCS reduced the stress to the myocardium resulting from transient myocardial 
ischemia, a fact likely related to pre-emptive SCS rendering the myocytes downstream from the 
occlusion ischemia-resistant. 
 In support of this concept, prior studies from our laboratory have demonstrated that both 
high thoracic (Southerland and others 2007) and high cervical SCS (paper in press) reduce infarct 
size to transient MI.  Previous studies have demonstrated several intracellular mechanisms, i.e. α1–
PKC pathway and ß-PKA pathway, that cause the protection of myocytes against ischemic stress 
(Southerland and others 2007; Yellon and Downey 2003).  These intracellular mechanisms 
themselves may play a significant role in the SCS-induced protection of the myocardium against 
ischemic stress that was observed in this study (Wu and others 2008). 
 Previous investigators have suggested that SCS-mediated protection of peripheral tissues is 
related to imposed efferent function on afferent projections, specifically to antidromic activation of 
primary afferents with resultant release of neuropeptides to target tissues (Linderoth and others 
1991).  We found no corresponding data for first order cardiac-related afferents projecting centrally 
in either the DRG or nodose ganglia.  We further determined that if central projections to the 
recorded DRG populations were selectively interrupted while maintaining all other DRG intact, high 
thoracic SCS was still capable of truncating the MI-induced increase in neural activity.  Together 
with the antidromic experiment described above and the induced changes in LV dp/dt, these data 
point to the importance of SCS-induced changes in myocytes themselves (e.g. rendering them 
ischemic-resistant) as the primary mechanism for decreased afferent response to ischemic stress. 
 Perspectives and significance:  Data derived from this study indicate that while SCS can modify 
the stress of transient myocardial ischemia, as evidenced by its capacity to reduce the influence of 
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myocardial ischemia on +LVdp/dt, it does not directly affect the capacity of cardiac afferent 
neurons to transduce an ischemic event.  We conclude that any neuronal modification so induced 
was a consequence of their transduction of an altered ventricular milieu.  Pain studies have suggested 
that pre-emptive SCS renders cardiomyocytes ischemic resistant and this process involve alterations 
in sympathetic efferent neuronal inputs to the heart (Southerland and others 2007).  In the clinical 
setting, patients are capable of tolerating increased levels of stress with SCS therapies (Mannheimer 
and others 1993).  However, when stressors reach a critical threshold, as indicated by indices such as 
ST segment shift during a progressive exercise test (Mannheimer and others 1993), pain is perceived.  
These data, in conjunction with that presented herein, demonstrate the increased ischemia resistance 
exerted by neuromodulation therapies.  This effect is likely reflective of induced changes in the 
myocytes (Southerland and others 2007) and in the blunting of excessive MI-induced reflex 
activation of efferents within the cardiac nervous system (Ardell and others 2009; Armour and 
others 2002; Foreman and others 2000). 
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Abstract 
Our objective was to determine if atrial fibrillation (AF) results from excessive activation of intrinsic 
cardiac neurons (ICNs) and, if so, whether select subpopulations of neurons therein represent 
therapeutic targets for suppression of this arrhythmogenic potential. Trains of 5 electrical stimuli 
(0.3-1.2mA, 1ms) were delivered during the atrial refractory period to mediastinal nerves (MSN) on 
the superior vena cava to evoke AF. Neuroanatomical studies were performed by injecting the 
neuronal tracer DiI into MSN sites that induced AF. Functional studies involved recording of 
neuronal activity in situ from the right atrial ganglionated plexus (RAGP) in response to MSN 
stimulation (MSNS) prior to and following neuromodulation involving either pre-emptive spinal 
cord stimulation (SCS, T1-T3, 50 Hz, 200 ms duration) or ganglionic blockade (hexamethonium, 5 
mg/kg). The DiI neuronal tracer labeled a subset (13.2%) of RAGP neurons, which also co-localized 
with cholinergic or adrenergic markers. A subset of Dil labeled RAGP neurons were non-
cholinergic/non-adrenergic. MSNS evoked a ~4-fold increase in RAGP neuronal activity from 
baseline which SCS reduced by 43%. Hexamethonium blocked MSNS evoked increases in neuronal 
activity. MSNS evoked AF in 78% of right-sided MSN sites, which SCS reduced to 33% and 
hexamethonium reduced to 7%. MSNS induced bradycardia was maintained with SCS, but mitigated 
by hexamethonium. We conclude that MSNS activates subpopulations of intrinsic cardiac neurons, 
thereby resulting in the formation of atrial arrhythmias leading to atrial fibrillation. Stabilization of 
ICN local circuit neurons by SCS or the local circuit and autonomic efferent neurons with 
hexamethonium reduces the arrhythmogenic potential. 
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Introduction 
Excessive activation of select inputs to the intrinsic cardiac nervous system (ICN) are known to 
elicit atrial arrhythmias in normal (9; 22; 28)  and pathophysiological states (11; 30). Discrete 
activation of the axons in select mediastinal nerves can reproducibly elicit self-terminating periods of 
atrial tachyarrhythmias/fibrillation (ATF) (9). Mediastinal nerves are made up of sympathetic and 
parasympathetic efferent neuronal inputs into the intrinsic cardiac nervous system, as well as afferent 
axons arising from cardiac tissues (9). They likewise contain interganglionic connections mediated 
via local circuit neuronal projections (15) which sub-serve, in part, to coordinate peripheral reflex 
function (7; 34). Because excessive activation of the axons in select mediastinal nerves reproducibly 
elicits self-terminating periods of atrial tachyarrhythmias/fibrillation (ATF), this animal model has 
been employed to study the neuropharmacological basis of neurally-evoked atrial arrhythmias (9; 
28). 
The extent of involvement of various ICN neuronal populations in mediating AF has yet to be 
determined. Secondly, whether neuronally-induced atrial arrhythmias involve excessive activation of 
select populations within the intrinsic cardiac neurons remains unknown. Since neuromodulation 
therapy has been shown to suppress the ability of mediastinal nerves to induce AF (10), it has been 
postulated that spinal cord stimulation (SCS) acts to suppress the responsiveness of the ICN to 
excessive sensory inputs arising from the diseased myocardium in the induction of such arrhythmias 
(10; 13). Likewise, pharmacological neuromodulation that blocks neuronal transmission within the 
ICN has been shown to decrease the propensity of ATF formation secondary to mediastinal nerve 
stimulation (9; 28). While these neuromodulation therapies are known to act upon the peripheral 
autonomic nervous system (4; 13), how they target the ICN to reduce ATF formation initiated by 
excessive mediastinal nerve stimulation has yet to be determined. 
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To understand how neurons within the ICN respond to excessive inputs from extracardiac sources 
(as mimicked by mediastinal nerve stimulation) in the induction of ATF, the present study was 
designed to test the following hypotheses: 1) mediastinal nerve stimulation activates select neuronal 
populations within the ICN in the induction of ATF; 2) stabilization of those populations within the 
intrinsic cardiac nervous system via neuromodulation (electrical or pharmacological) blunts the 
capacity of the ICN to respond to excessive inputs and thereby suppress its potential to induce atrial 
tachyarrhythmias. This study identified the fact that excessive inputs to the ICNs in the induction of 
ATF does indeed primarily involve excessive activation of local circuit neurons therein, sparing, for 
the most part, direct efferent outflows to the heart. 
Methods 
Animal Preparation: Thirty mongrel dogs (either sex), weighing 18.6-26.9 kg, were used in this study. 
All experiments were performed in accordance with the guidelines for animal experimentation 
described in the “Guiding Principles for Research Involving Animal and Human Beings” (1). The 
Institutional Animal Care and Use Committee of the East Tennessee State University approved 
these experiments. 
Neuronal Tracer Injection: Animals (n=2) were premedicated with sodium thiopental (15 mg/kg, i.v.), 
intubated and anesthetized using 2% isoflurane. Heart rate and blood pressure were continuously 
monitored (Surgivet Advisor Monitor, Smiths Medical) with depth of anesthesia determined by 
corneal reflex, jaw tone, and hemodynamic parameters. Body temperature was maintained via a 
circulating water heating pad (Gaymar T/Pump, Gaymar Industries Inc., Orchard Park, NY). Using 
aseptic techniques, a right thoracotomy was performed at the 4th intercostal space; an incision was 
made into the pericardial sac to expose the superior vena cava at the pericardial reflection into the 
right atrium, and a pericardial cradle formed. Using techniques described previously (9; 28), 
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mediastinal nerve projection sites were identified on the superior vena cava at the pericardial 
reflection in which train electrical stimuli delivered during the atrial refractory period reproducibly 
induced transient periods of atrial fibrillation. Ten μL boluses of 0.1 M solution of 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) were then injected via a 1 cc Hamilton 
syringe into that site. Following tracer injection, the pericardium and thoracic cavity were closed in 
layers and residual air removed from the chest via a chest tube. Buprenorphine (0.01 mg/kg, i.m. or 
i.v.) was administered pre- and post-operatively for pain management. Antibiotic therapy 
(intramuscular cefazolin or oral cephalexin, 22 mg/kg) was administered twice daily prior to surgery 
and continued for 2 days postoperatively. Animals were recovered for 2 days following surgery to 
allow for transport of the tracer. The animals were re-anesthetized in the manner described above 
and a thoracotomy performed to collect the right atrial ganglionated plexus (RAGP), an aggregate of 
intrinsic cardiac neurons associated with control of atrial electrical and mechanical function (5; 27). 
Immunohistochemistry: The RAGP cardiac ganglia were briefly washed in saline and then transferred to 
a 4°C fixative solution containing 4% paraformaldehyde and 0.2% picric acid in phosphate buffered 
saline (PBS, pH 7.3). Tissues were fixed at 4°C for 24 hr. They were then transferred to 20% sucrose 
in PBS (4°C, 4 days) for cryo-protection, frozen on powdered dry ice, and stored in sealed tubes at -
80°C until processed. The ganglia were sectioned at a thickness of 16 μm using a Leica CM 3050S 
cryostat (Leica Microsystems Inc., Bannockburn, IL). Adjacent sections were collected on separate 
chrome-alum gelatin coated slides such that six representative sets of tissue sections were obtained 
from each tissue sample. Slide-mounted sections were stored in closed slide boxes at -20°C prior to 
immunohistochemistry. Single- and double-labeling of sections were studied at room temperature 
using standard methods previously described (19). Digitonin was used in solution instead of triton 
X-100 to minimize loss of DiI during processing (24). Briefly, slides were rinsed with 0.1 M PBS 
(pH 7.3), permeabilized in PBS containing 1000 μg/ml digitonin (Cat # 300411, EMD Biosciences, 
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San Diego, CA) and 0.5% bovine serum albumin (BSA), and blocked for 2 hr in PBS containing 
10% normal donkey serum (Cat # S30, Millipore, Billerica, MA), 1% BSA and 1000 μg/ml digitonin. 
Tissues were then incubated overnight in a buffer containing either rabbit anti-Protein Gene 
Product 9.5 (PGP 9.5, AB1761, Millipore, Billerica, MA) or various combinations of sheep anti-
tyrosine hydroxylase (TH, AB1542, Millipore, Billerica, MA), goat/rabbit anti-choline 
acetyltransferase (ChAT, AB144P, Millipore, Billerica, MA /AB-N34, Advanced Targeting Systems, 
San Diego, CA) or guinea pig anti-vesicular acetylcholine transporter (VAChT, AB1588, Millipore, 
Billerica, MA). After washing with PBS, tissues were incubated for 2 hr with donkey anti-rabbit 
secondary antibodies conjugated to AlexaFluor 488 and donkey anti-sheep secondary antibodies 
conjugated to AlexaFluor 647 (A-21206, A-21448, Invitrogen, Carlsbad, CA) and washed with PBS. 
Coverglasses were attached with Citifluor mounting medium (Ted Pella, Redding, CA) and sealed 
with clear nail polish. Negative control slides were processed similarly without using primary 
antibodies. The selectivity of fluorescence filters and the presence of co-localized markers were 
confirmed in several sections obtained from each animal by sequential scanning with a Leica TCS 
SP2 confocal microscope (Leica Microsystems Inc., Bannockburn, IL). The software used to 
discriminate DiI-positive neuronal somata from background was ImageJ. This was performed on 
images obtained by confocal microscopy. The neurochemical phenotype of DiI labeled neurons was 
identified based on overlay confocal images. 
Hemodynamic recording: In the remaining canines (n=28), animals were anesthetized and instrumented 
for recording of neuronal activity from the RAGP ganglia. Responses (neural and atrial electrical 
activity) to mediastinal nerve stimulation were evaluated prior to and following neuromodulation 
using either ganglionic blockade (n=12) or spinal cord stimulation (n=16) (see below). Anesthesia 
was maintained during surgery using 2% isoflurane with depth of anesthesia determined by corneal 
reflex, jaw tone, and hemodynamic parameters. Following completion of the surgery, anesthesia was 
84 
 
changed to α-chloralose (75 mg/kg i.v. bolus), with repeat doses (12.5 mg/kg i.v.) administered as 
required throughout the duration of each study. Body temperature was maintained via a circulating 
water heating pad (Gaymar T/Pump, Gaymar Industries Inc., Orchard Park, NY). The left femoral 
artery and vein were catheterized to record arterial blood pressure and to allow for anesthetic, fluid 
replacement, and pharmacological agent delivery, respectively. The right femoral artery was 
catheterized and left ventricular pressure was measured via a Mikro-Tip Pressure Transducer 
Catheter (Millar Instruments, Houston, TX). Heart rate was monitored via a Lead II 
electrocardiogram. 
Spinal cord stimulation (SCS): For the SCS treatment group, each animal was placed in the prone 
position and the spinal epidural space was penetrated percutaneously with a Touhy needle through a 
small skin incision in the caudal dorsal thorax as detailed previously (4). An eight-pole lead (Octrode, 
Advanced Neuromodulation Systems, Plano, TX) was advanced rostrally in the epidural space to the 
T1-T3 spinal cord level. The tip of the lead was positioned slightly to the left of midline using 
anterior-posterior fluoroscopy. The rostral pole was positioned at T1 while the caudal pole was 
positioned at T3 level. Proper electrode placement was determined via electrical current delivered to 
the rostral and caudal poles using a stimulus isolation unit and constant current generator (PSIU6, 
Grass Instruments, Quincy, MA) connected to a stimulator (S88, Grass Instruments, Quincy, MA). 
SCS was delivered at 50 Hz and 200 μs duration, stimulus parameters that have previously been 
shown to induce neuromodulation of extracardiac intrathoracic and intrinsic cardiac ganglia neurons 
during periods of acute cardiac stress (4; 13). Motor threshold (MT) intensity was determined as the 
lowest current that induced muscle contractions in the proximal forepaw and shoulder. Animals 
were rotated to the supine position for the experimental protocols with MT rechecked in this 
position. MT was checked periodically during the experiments and did not vary significantly from 
initial levels (0.25±0.02 mAmp). 
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Mediastinal nerve stimulation - MSNS: Following thoracotomy, an incision was made into the pericardial 
sac and a pericardial cradle formed. A bipolar electrode was affixed to the right atrium, 1 cm dorsal 
to the SA node to record atrial electrograms. Right-sided mediastinal nerves were identified visually 
on the ventral and ventro-lateral surface of the intrapericardial aspects of the superior vena cava and 
then stimulated using techniques detailed elsewhere (9; 28). Briefly, trains of five electrical stimuli 
(0.3-1.2 mA, 1 ms duration, 5 ms pulse interval) were delivered for up to 20 seconds to select 
mediastinal sites during the refractory period on each atrial beat, as triggered off the reference atrial 
electrogram. This was done to avoid direct atrial capture. Electrical stimuli were delivered via a 
roving bipolar probe electrode (1.5 mm spacing) connected to a constant current generator (PSIU6, 
Grass Instruments, Quincy, MA) affixed to a Grass S88 stimulator (S88, Grass Instruments, Quincy, 
MA). The stimulator was externally controlled by a computer running LabChart5 (ADInstruments, 
Colorado Springs, CO) interfacing with a Powerlab 4/30 (ADInstruments, Colorado Springs, CO) 
and triggered by atrial wavefront detections. Active sites were identified by the creation of atrial 
tachyarrhythmias (including atrial fibrillation) when exposed to focal electrical stimuli. Each active 
site was marked with India ink for repeat stimulation. Two to four active sites were identified in each 
animal. Contact between the bipolar electrodes and tissue was discontinued immediately after the 
onset of the atrial tachyarrhythmia. 
Neuronal Recording: Activity generated by neurons in the right atrial ganglionated plexus (RAGP) was 
recorded in situ, as reported previously (3; 14). Briefly, to decrease epicardial motion during each 
cardiac cycle, a circular ring of stiff wire was placed gently on the epicardial fat on the ventral surface 
of the right atrium - a region known to contain the RAGP. A tungsten microelectrode (250 μm 
diameter and exposed tip of 1 μm; impedance of 9-11 MΩ at 1000 Hz), mounted on a 
micromanipulator, was lowered into this fat using a microdrive. The ganglionated plexus therein was 
explored and electrical signals so derived were led into a differential preamplifier (BMA-831, CWE 
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Inc., Ardmore, PA) with a high impedance head stage (band width set at 300 Hz to 10 kHz). Signals 
were further amplified by a battery-driven pre-amplifier (5113 Pre-Amp, Signal Recovery, Oak 
Ridge, TN) (band width 100 Hz to 2 kHz). Amplified neuronal signals, together with recorded 
cardiovascular indices, were digitized (Cambridge Electronics Design, power 1401 data acquisition 
system) and analyzed using the Spike 2 software package (Cambridge Electronics Design). 
Neuronal activity was identified as action potentials with signal to noise ratios greater than 3:1. The 
activity generated by individual neuronal somata was identified by the amplitude and configuration 
(waveform recognition) of these recorded action potentials, using the Spike 2 program. Using these 
techniques and criteria, action potentials generated by individual somata and/or dendrites, rather 
than axons of passage, can be recorded for extended periods of time (3; 4; 14). 
Treatment Groups: Animals were divided randomly into two neuromodulation treatment groups, one 
that had SCS electrode implantation (n=16) and another that evaluated the effects of ganglionic 
blockade on arrhythmia responses evoked by MSNS (n=12). For each of these animals, 2-3 
mediastinal sites were first identified that reproducibly evoked atrial arrhythmias. In 8 of these 
animals (4 from each group), time controls were done to verify reproducibility of evoked responses 
to MSNS over time. For the SCS treatment group, electrical stimuli (50 Hz, 200 μs duration, 90% 
Motor threshold) were delivered to the T1-T3 spinal level for 20 min. Responses to MSNS 
stimulation were evaluated prior to and 5-30 min. following SCS. For the hexamethonium treatment 
group, responses to MSNS stimulation were evaluated prior to and 15 min after hexamethonium 
administration (5 mg/kg, i.v.). 
Data Analysis: Action potentials arising from a site within each RAGP studied were characterized by 
means of their differing amplitudes and configurations (waveform recognition via the Spike2 
program: Cambridge Electronic Design, Cambridge, England CED). Neuronal activity responses 
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elicited by MSNS were evaluated by comparing activity generated immediately before stimulation 
with data obtained during nerve stimulation; neuronal activity data are presented as impulses per 
second (imp/sec). Characterization of atrial rhythms evoked by MSNS included latency and duration 
of atrial arrhythmias; this analysis was performed offline using Spike 2. Data are expressed as means 
± SEM. Sigmastat 3.1 (Systat software) was used to test for differences between groups by ANOVA 
with post-hoc comparisons (Holm-Sidak or Tukey method for comparisons, depending on results of 
normality tests). A significance of p< 0.05 was used for these experiments. 
Results: 
Neuroanatomical data: Select mediastinal nerve projections to the right atrial ganglionated plexus were 
identified that, when subjected to trains of focal electrical stimuli delivered during the atrial 
refractory period, reproducibly induce transient periods of atrial fibrillation. DiI was then micro-
injected into the wall of the superior vena cava at that nerve site. RAGP tissues harvested 2 days 
after application of Dil to that mediastinal nerve site identified 13.2% of RAGP neuronal soma 
labeled. PGP 9.5 (green) labeled all neuron soma in these RAGP. Some neuronal somata 
demonstrated co-localization of PGP 9.5 and Dil (Fig. 1). The neurochemical profile of Dil labeled 
neurons within these RAGP demonstrated that 16.7% of Dil labeled neurons also labeled for 
cholinergic marker choline acetyltransferase (ChAT) (Fig. 2). 22.2% of Dil labeled neurons labeled 
for the noradrenergic marker tyrosine hydroxylase (TH); 55.6% of Dil labeled neurons co-localized 
with markers for ChAT and TH. The remaining 5.5% of Dil labeled neurons did not exhibit either 
noradrenergic or cholinergic markers. 
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Figure 1. Characterization of neuronal cell bodies in the RAGP, labeled with the tracer (Dil) 
injected into right-sided mediastinal nerve sites where electrical stimulation (MSNS) induced AF. 
PGP 9.5 labeled all intrinsic cardiac neurons (ICN) green and DiI labeled neurons projecting from 
MSNS responsive sites in red. Co-localization of PGP 9.5 and DiI is indicated by yellow (arrows 
indicate double-labeled soma) in the overlap figure (OVL). 13.2% of PGP 9.5 labeled neurons 
within the RAGP co-localized with Dil. Scale bar equals 75 um. 
89 
 
 
Figure 2. Neurochemical profile of RAGP neurons labeled with the tracer (Dil) injected into right-
sided mediastinal nerve sites where electrical stimulation (MSNS) induced AF. Neurons were 
immunolabeled for choline acetyltransferase (ChAT; green label), tyrosine hydroxylase (TH; blue 
label) and DiI (red label). Solid arrow indicates co-localization of ChAT and DiI (16.7% of neurons). 
Open arrow indicates co-localization of TH and DiI (22% of neurons). Open arrowheads indicate 
co-localization of DiI with both ChAT and TH (55.6% of neurons). Solid arrowhead indicates a DiI 
neuron that did not label with either TH or ChAT markers (5.5% of neurons). Scale bar equals 40 
um. 
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Intrinsic Cardiac Neuronal Activity: The activity generated by RAGP neurons increased in response to 
MSNS (Fig. 3). Mediastinal nerve stimuli induced an initial bradycardia (average 23.7±3.5% change 
from baseline cycle length) that transitioned rapidly to atrial fibrillation/flutter (AF/AFl). The 
average latency of such responses was 1.3±0.2 sec. from stimulus onset; the average duration of 
AF/AFl was 26.4±6.0 sec. Intrinsic cardiac neuronal activity increased in association with stimulus 
onset; neuronal activity increased further during the induction of AF. This enhancement of activity 
persisted during the initial period following sinus rhythm restoration (Fig. 3). On average, MSNS 
evoked ~4 fold increase in neuronal activity (Fig. 5, left panels; 0.29±0.08 imp/s to 1.20±.16 
imp/sec, p<0.001). 
Figure 3. RAGP neuronal activity and corresponding cardiac electrical activity in response to 
MSNS. Arrows indicate delivery of 4 successive burst stimuli to a right-sided mediastinal nerve 
located on the SVC at the level of the pericardial reflection. MSNS induced an increase in RAGP 
neuronal activity, which persisted after stimulus cessation. Neuronal activity was further enhanced 
once the arrhythmia was induced. Vent. – ventricle, RAGP activity – right atrial ganglionated plexus 
neuronal activity Trace three (activity in impulses per second) indicates ongoing 1 sec bin summed 
activities. Note that during burst stimuli heart rate was reduced from 83 to 76 bpm immediately 
prior to initiation of atrial fibrillation. Insert shows expanded trace for one of RAGP neurons 
recorded. 
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Neuronal responses evoked by MSNS were altered by both pre-emptive SCS and nicotinic receptor 
blockade. While, SCS did not decrease basal neuronal activity (Fig 4 and Fig 5 top panel; 0.27±0.10 
imp/sec versus 0.22±0.10 imp/sec), MSNS-induced changes in RAGP activity was suppressed 
significantly after 20 min. of pre-emptive SCS (1.19±0.17 to 0.68±0.18 imp/sec, p<0.001) (Fig. 5, 
top panel). Hexamethonium administration likewise did not affect basal neuronal activity (Fig. 5, 
bottom), yet completely suppressed the MSNS-evoked increase in RAGP neuronal activity 
(0.38±0.20 to 0.55±0.19 imp/sec; p=.143) (Fig. 5, bottom panel). 
Figure 4. Neuronal activity recorded from the same RAGP site depicted in Fig. 3 demonstrating the 
effects of MSNS repeated 5 min after 20 min pre-emptive SCS. Note that following SCS, MSNS was 
ineffectual in evoking atrial arrhythmias. 
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Figure 5: Effects of 
MSNS on RAGP 
neuronal activity recorded 
prior to and following 
pre-emptive SCS (top 
panel) or hexamethonium 
administration (bottom 
panel). MSNS initiated a 
~4 fold increase in 
neuronal activity. Pre-
emptive SCS blunted the 
ability of MSNS to 
increase neuronal activity. 
Hexamethonium blocked 
MSNS evoked increase in 
neuronal activity. * 
p<.002 versus baseline; + 
p<.001 versus control. 
 
 
 
 
 
 
 
MSNS-induced bradycardia: Figure 6 summarizes the effects of hexamethonium (top panel) or pre-
emptive SCS (bottom panel) on the magnitude of the initial MSNS-evoked bradycardia. In the 
hexamethonium treated group, while basal cardiac cycle length increased (454.3±16.6 versus 
507.9±20.5 ms, p=.009), the absolute MSNS-evoked bradycardia was similar over time (535.6±16.3 
versus 540.1±20.5 ms, p=.78). Moreover, even following nicotinic receptor blockade, MSNS 
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continued to increase cardiac cycle length (507.9±23.8 baseline to 540.1±20.5 MSNS, p<.001), albeit 
at a lesser magnitude compared to control. In contrast, pre-emptive SCS did not affect the MSNS-
evoked bradycardia (23.7±3.5%: 433.6±11.4 to 532.0±11.9 ms, p<0.001). 
Figure 6. Mediastinal 
nerve stimulation-induced 
an initial atrial bradycardia 
before and following 
hexamethonium 
administration (top panel) 
or pre-emptive SCS 
(bottom panel). * p<.001 
versus basal; + p<.01 
versus control. 
 
 
 
 
 
 
 
 
 
Time controls: Time controls for both treatment groups exhibited similar MSNS evoked changes in 
RAGP neuronal activity (0.21±0.05 to 1.00±.40 imp/sec versus 0.15±0.04 to 1.02±.11 imp/sec, 
basal to MSNS). Time controls also demonstrated consistent responses in basal cycle length 
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(420.3±9.6 ms versus 415.8±7.9 ms, p=.99) and equivalent evoked changes in cardiac cycle length 
with MSNS onset (526.1±22.2 ms versus 507.3±20.9ms; p=0.70). 
Atrial Rhythms: Atrial rhythm responses to MSNS were studied before (panel A: control 94 active 
sites) and following either hexamethonium administration (panel B: 28 of the 94 sites) or pre-
emptive SCS (panel C: 66 of the 94 sites). In control states, the predominant atrial rhythm evoked by 
right-sided MSNS was AF/AFl (77.7%); sinus bradycardia (12.8%), sinus tachycardia (4.2%), and 
other rhythms (5.3%) were induced less frequently. Time controls demonstrated no significant 
change in these response characteristics. Following ganglionic blockade, MSNS evoked AF/AFl 
from only 7.1% of the nerve sites stimulated (Fig. 7, panel B); sinus rhythm/bradycardia was the 
predominant rhythm (82.2% of sites). 
Figure 7. Types of atrial 
rhythms evoked during 
mediastinal nerve stimulation 
prior to (A, control) and 
following treatment with 
hexamethonium (panel B) or 
pre-emptive T1-T3 SCS (panel 
C). The number of stimulation 
sites in each group is indicated 
above each chart; the number 
of arrhythmias elicited in each 
subgrouping are also indicated. 
AF/AFL – atrial 
fibrillation/atrial flutter. 
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Following pre-emptive SCS, the predominant atrial rhythm evoked by MSNS shifted to sinus 
bradycardia (56.2%). Not only did pre-emptive SCS reduce the number of mediastinal sites that 
evoked AF (77.7% to 33.3%, Fig. 7), but for the residual active sites the latency to evoke such AF 
increased (1.03±0.12 to 1.63±0.20 sec; p=.004) and duration of such evoked AF decreased 
(33.8±9.9 to 14.8±3.0 sec; p=.047) (Fig. 8). Time controls exhibited no change in the latency to AF 
onset (1.26±0.29 to 1.15±0.25 sec; ns) or the duration of MSNS-evoked AF (21.5±13.9 to 22.6±6.8 
sec; n.s.). 
Figure 8. SCS-induced 
changes in AF 
characteristics in SCS-
resistant stimulation sites. 
Even when atrial fibrillation 
persisted from 22 sites 
following pre-emptive SCS, 
its latency increased and 
duration decreased. * p<.05 
from control. 
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Discussion: 
Excessive inputs to the intrinsic cardiac nervous system via, for instance, activating select 
mediastinal nerve inputs to that system, are known to initiate ectopic atrial activation that can lead to 
alterations in atrial rhythms (9; 10 28). As such, it has been proposed that selective activation of 
inputs to the ICN leads to excessive and heterogeneous activation within that nervous system to 
induce atrial arrhythmias (9). 
In fact, select neuronal receptors (specifically nicotinic and α-adrenergic ones) have been implicated 
in mediating neuronally-induced atrial arrhythmias (9; 28). In agreement with that concept, systemic 
administration of hexamethonium or α-adrenergic receptor blocking agent obtunds the ability of 
MSNS to generate atrial dysrhythmias (9; 28). In addition to such pharmacological neuromodulation, 
neuromodulation involving electrical stimulation of the dorsal, thoracic spinal cord can similarly 
decrease the ability of the intrinsic cardiac nervous system to generate atrial arrhythmias when 
excessively activated (10). While previous studies have inferred the involvement of specific 
subpopulations of intrinsic cardiac neurons in neural mechanisms associated with atrial arrhythmias, 
this study demonstrates the specifics of the neural-substrate so involved and the potential to target it 
therapeutically to manage atrial arrhythmias. 
The ICN has been traditionally thought to represent a simple relay station for parasympathetic 
efferent innervation of the heart (21). However, recent research has altered this view by elucidating 
the presence of a variety of intrinsic cardiac neurochemical phenotypes in conjunction with different 
functional classes of neurons including afferent, efferent and local circuit neurons that interact 
reflexly to modulation regional cardiac electrical and mechanical activities (6; 16; 26). Most intrinsic 
cardiac neurons display immunoreactivity to cholinergic markers, some without cholinergic inputs 
(18). Other intrinsic cardiac neurons, including human intrinsic cardiac ganglia, express an 
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adrenergic phenotype (17; 18; 32). Moreover, various of these neurons are also innervated by 
peptidergic, nitrergic, and noradrenergic fibers (16; 18; 29). In accord with such anatomy, in this 
study immunohistochemistry analysis demonstrated that the populations of ICN neuronal somata 
receiving inputs from mediastinal nerves that induce arrhythmogenic activity express cholinergic 
and/or adrenergic markers. In addition, there is another population of intrinsic cardiac neurons that 
appear to be involved in the genesis of atrial tachyarrhythmias that are neither cholinergic nor 
adrenergic in function. 
It has been reported that the largest population of intrinsic cardiac neurons, represented by local 
circuit neurons, has the ability to process afferent and efferent inputs, thereby contributing to 
efferent neuronal control over regional cardiac function (6). As such, this population receives not 
only cardiac sensory inputs (3) but also efferent inputs from both limbs of the autonomic nervous 
system (8; 14). The integration of afferent and efferent inputs, combined with the capacity of 
intrinsic cardiac local circuit neurons to interact with neurons within other intrathoracic ganglia, 
comprises organ-level neuronal processing for functional control (7; 15; 34; 36). 
The present study demonstrates that MSN activation in the induction of atrial arrhythmias is 
associated with alterations in the activity generated by populations of intrinsic cardiac neurons that 
represent different phenotypical subtypes (Fig. 3). Furthermore, these data demonstrate that 
excessive inputs to the ICN can indeed result in activation of neuronal populations therein – such 
neurons responding with activity rates considerably above control levels. As such, these data 
confirm the fact that atrial electrical instability can be related to excessive activation of select 
populations of ICN neurons. When synaptic efficacy within the ICN is compromised by nicotinic 
blockade, this arrhythmogenic potential is reduced in response to nerve imbalances within the 
cardiac nervous system. However, such ganglionic blockade is associated with major deficits in 
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efferent outflow to the periphery (33). On the other hand, SCS apparently imparts an obtunding 
effect on such excessive excitation of intrinsic cardiac neurons such that in many instances excessive 
mediastinal nerve inputs failed to enhance intrinsic cardiac neuronal activity (Fig. 4). Yet efferent 
function to the heart is maintained following SCS (Fig. 6). This, in turn, may explain why SCS 
appears to influence cardiac indices (12; 23), albeit in a relatively minor fashion (13; 20). It does so 
by restraining reflex pathways within intrathoracic autonomic ganglia associated with cardiac control 
(4; 13). SCS likewise does not blunt the chronotropic or dromotropic responses associated with 
extracardiac stimulation of principal parasympathetic or sympathetic projections to the heart (25). 
On the other hand, the reduction in ICN neuronal activation induced by excessive mediastinal nerve 
inputs presumably was the result of SCS modulation/suppression of local circuit neurons, c.f. figure 
3. In fact, that population represents the largest target population within the ICN (8; 14). That such 
neuronal responsiveness to excessive inputs was obtunded is further demonstrated by the fact that 
more than half of previously responsive neurons identified were no longer activated by MSNS 
following SCS. 
Perspectives and Significance: It is becoming apparent that neuronal control of the heart is significantly 
more complex than previously thought (6). Multiple tiers of neuronal processing occur within the 
cardiac neuronal hierarchy that ultimately acts to coordinate neuronal inputs to the heart (4; 7; 13). 
Stresses, either pathological or physiological, may disrupt the balance of efferent neuronal inputs 
that can lead to altered cardiac function (6; 22). As such, novel therapies that overcome any such 
imbalance in cardiac control, as represented by neuromodulation of the ICN via SCS, may moderate 
excessive activation of the ICN in response to transduction of pathological cardiac stressors. Other 
electrical neuromodulation-based therapies, such as low-level vagosympathetic stimulation, may 
target peripheral aspects of the cardiac nervous system to reduce the arrhythmogenic potential (31; 
35), but their respective neuronal targets have yet to be established (2). 
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Indeed, data derived from this study indicate that SCS can 1) stabilize intrinsic cardiac local circuit 
neurons in the presence of excessive extracardiac inputs, thereby obtunding any capacity to induce 
atrial arrhythmias and 2) do so without affecting direct autonomic efferent neuronal outflows to the 
heart to compromise cardiac function. In contrast, nicotinic receptor blockade suppressed not only 
the capacity of local circuit neurons to become excited but also autonomic efferent projections that 
influence cardiac indices. Such data delineate the possibility of targeting local as opposed to central 
derived inputs to the heart. They also support the thesis that SCS may represent a novel therapeutic 
strategy to counteract pathologically-induced excessive activation of the ICN that would otherwise 
lead to atrial arrhythmia induction. 
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CHAPTER 5 
Summary 
 Chapter 2 determined that cervical SCS decreased infarct size resulting from MI by using 
dorsal spinal column projections to modify adrenergic efferent functions.  Dorsal column 
transection or adrenergic receptor blockade eliminated the infarct size reduction effect of cervical 
SCS.  Cervical SCS also decreased the activation of spinal cord neurons in laminae I-V that resulted 
from MI.  In the presence of cervical SCS, β-adrenergic blockade and cervical vagal transection 
eliminated the incidence of SCD while muscarinic blockade had no effect.  The data presented 
indicate that cervical SCSC utilizes both adrenergic and cholinergic efferent mechanisms to stabilize 
cardiomyocytes and the arrhythmogenic potential in response to ischemic stress. 
 Chapter 3 found that cardiac primary afferent neurons in the nodose and DRG were 
activated by transient myocardial ischemia.  High thoracic SCS did not directly activate cardiac 
primary afferent neurons in the DRG or nodose, yet it did mitigate the MI-induced increase in 
cardiac primary afferent neuronal activity in both afferent populations.  Our data indicate that pre-
emptive SCS exerts this effect by altering the sensory milieu of the stressed heart rather than by 
direct antidromic activation of primary afferent fibers. 
 Chapter 4 demonstrated that intrinsic cardiac neurons have numerous distinct 
neurochemical phenotypes including adrenergic, cholinergic, adrenergic/cholinergic, and non-
adrenergic/non-adrenergic phenotypes.  MSNS activated distinct subpopulations of intrinsic cardiac 
neurons within associated periods of AF.  Neuromodulation therapy, exerted by thoracic SCS or 
hexamethonium, decreased the activation of the intrinsic cardiac neurons resulting from MSNS and 
stabilized the atrial arrhythmogenic substrate. The stabilization effects on AF induction of 
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hexamethonium were greater than those of thoracic SCS.  Our data indicate that hexamethonium 
targets efferent and local circuit neurons while SCS preferentially modulates local circuit neurons. 
 
Organization of the Cardiac Nervous System for Control of Normal and Stressed Hearts 
 The cardiac nervous system consists of afferent, efferent, and local circuit neurons that 
interact to control heart function (Armour 1999; 2004).  Cardiac-related afferent neurons transmit 
sensory signals (mechanosensory and/or chemosensory) via the DRG to the spinal cord for 
sympathetic afferents and via nodose ganglia to the brainstem for parasympathetic afferents 
(Armour 1999; 2004; Cheng and others 1999; Hopkins and Armour 1984; Marieb 2004).  For 
control of cardiac sympathetic function, brainstem cardiovascular-related centers send projections 
down to the thoracic spinal cord to the intermediolateral cell column (origin of sympathetic pre-
ganglionic neurons)with subsequent projections from these neurons to the 
intrathoracic/extracardiac ganglia (Marieb 2004).  These ganglia, in turn, send efferent sympathetic 
postganglionic projections to the heart (Marieb 2004).  Parasympathetic efferent pathways travel 
from the brainstem through the vagi to the heart making the pre- to post-ganglionic connections at 
the intrinsic cardiac ganglia (Armour 1999; 2004; Cheng and others 1999; Hopkins and Armour 
1984; Marieb 2004).  Contained within each of the autonomic ganglia of the cardiac nervous system 
are local circuit neurons that serve to connect afferent and efferent neurons within single ganglia and 
between different intrathoracic ganglia (Armour 2008).  The cardiac nervous system is organized in a 
series of nested feedback control loops (Armour 1999; 2004; 2008).  The most basic of these 
networks is the intrinsic cardiac nervous system, which is composed of numerous ganglia on the 
heart itself and serve to control regional cardiac function on a beat-to-beat basis (Armour 1999; 
2004; 2008).  Expanding outward from the intrinsic cardiac nervous system are the reflex control 
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networks contained within the intrathoracic “sympathetic” ganglia, with subsequent nodes for reflex 
processing contained within the spinal cord and brainstem (Armour 1999; 2004; 2008).  Higher 
centers of the brain can adjust cardiac control by modulating the cardiac nervous system, e.g. fight 
or flight, automatic response to pain, etc. (Marieb 2004).  Neural interactions between various levels 
of the cardiac nervous system allow for effective coordination of cardiac function at rest and during 
periods of cardiac stress (Armour 1999; 2004; 2008).  Included in these network interactions are 
propriospinal pathways within the spinal cord that allow for communication between spinal cord 
segments with the high cervical cord exerting major modulating effects on thoracic and lumbar 
reflex processing of organ specific functions (Chandler and others 1996; Ding and others 2008b; 
Foreman 1999; Marieb 2004). 
Research into numerous cardiac pathologies has elucidated characteristics of the cardiac 
nervous system and how it remodels during such stress (Cardinal and others 2004; Eliasson and 
others 1996; Mannheimer and others 1998; Southerland and others 2007).  One of those cardiac 
pathologies, MI, causes referred pain that is sensed in the arm or neck (Foreman 1999).  Those areas 
are part of the upper cervical somatic dermatomes, sections of the surface of the body whose 
sensory information enters the spinal cord at specific levels (Foreman 1999).  C1-C3 cervical spinal 
cord segments also receive parasympathetic and sympathetic afferent inputs, arising from both 
intrathoracic and visceral organs (Chandler and others 1996; Chandler and others 2000; Ding and 
others 2008a; Ding and others 2008b; Foreman 1999; Qin and others 2007a; Qin and others 2008; 
Qin and others 2004; Qin and others 2007b).  These findings led to the theory that the upper 
cervical spinal cord functions as a coordinating and processing center for sensory information 
passing up the spinal cord (Ding and others 2008a; Ding and others 2008b; Foreman 1999; Qin and 
others 2008).  The upper cervical region of the cord likewise uses intersegmental interconnections to 
interact with other levels of the cord (Qin and others 2007b).  As such, targeting the upper cervical 
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region with electrical neuromodulation has the potential to modulate reflex control of visceral 
functions including the heart (Ding and others 2008b; Qin and others 2007a; Qin and others 2008). 
Neuromodulation as a Therapeutic Approach for Control of Cardiac Nervous System and Heart 
 The first experiments to study how SCS affects the cardiac response to MI focused on the 
spinal segments where the cardiac afferent- and efferent-related pathways enter and exit the spinal 
cord (Hua and others 2004b; Qin and others 2008)  These clinical studies focused on retractable 
angina pectoris as the disease state to which SCS may have therapeutic benefits (Eliasson and others 
1996; Mannheimer and others 1993).  The results of those studies indicated that thoracic SCS 
decreased anginal pain symptoms, increased exercise tolerance, and delayed the onset of anginal 
symptoms(Eliasson and others 1996; Mannheimer and others 1993) .  These clinical observations 
prompted subsequent basic science research into how SCS exerted its anti-anginal effects (Cardinal 
and others 2006; Foreman and others 2000; Southerland and others 2007). 
Basic science studies have elucidated that thoracic SCS decreases intrinsic cardiac and 
extracardiac sympathetic neuronal reflex activation in response to MI stress and, if initiated pre-
emptively, decreases the infarct size resulting from MI (Ardell and others 2009; Foreman and others 
2000; Southerland and others 2007).  SCS does so without changing blood flow through coronary 
vessels at rest or during ischemic stress or by changing pressure-volume ratio within the left ventricle 
(Ardell and others 2009; Kingma and others 2001).  Transection of the ansae subclavian, 
interruption of afferent and efferent interconnections between the spinal cord and peripheral aspects 
of the cardiac nervous system, eliminates the cardioprotective effects of thoracic SCS (Cardinal and 
others 2006; Foreman and others 2000).  These data suggest that the SCS-induced effects are 
mediated by changing neural activity within the cardiac nervous system (Armour 1999; 2004; 2008). 
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 In this regard, SCS has demonstrated efficacy to modify neural processing in multiple levels 
of the cardiac nervous system hierarchy and the effects are long-lived (Armour 1999; 2004; 2008).  
Thoracic SCS decreases the cardiac nociception transduction in dorsal laminae (I-V) of the spinal 
cord, a response that affects not only evoked components of cardiac pain but also induced changes 
in autonomic functions (Ardell and others 2009; Qin and others 2008).  MI causes the release of 
several chemicals including bradykinin and adenosine into the milieu of the heart (Armour 1999; 
Herring and Paterson 2009).  Exogeneous application of those chemicals can therefore be used to 
mimic the effects of acute MI (Chandler and others 2000; Gnecchi-Ruscone and others 1995; Huang 
and others 1996).  Research shows that SCS can modulate the effects of MI by decreasing the 
responsiveness of the cardiac nervous system to those “algogenic” chemicals (Qin and others 2008).  
The exact nature of the mechanism through which SCS can decrease the responsiveness of the 
cardiac nervous system and therefore decrease the detrimental effects of MI remains to be 
determined (Armour 1999; 2004; 2008). 
Cardiac stress impacts cardiac electrical and mechanical function and the neurohumoral 
systems that modulates it (Armour 1999; 2004).  SCS reduces electrically-induced arrhythmia 
formation and naturally-occurring arrhythmias (Cardinal and others 2006; Issa and others 2005; 
Lopshire and others 2009; Zipes 2008).  For example, SCS has been shown to reduce the atrial 
arrhythmogenic potential arising from induced neural imbalance within the cardiac nervous system 
(Cardinal and others 2006).  Thoracic SCS also decreased the incidence of ventricular arrhythmia 
formation in response to transient ischemia following rapid ventricular pacing in an animal model 
with a previous ischemic injury (Issa and others 2005; Lopshire and others 2009).  Finally, SCS 
improves cardiac contractile function during recovery from experimentally-induced heart failure 
(Lopshire and others 2009).  Together, these data demonstrate the overall efficacy of SCS to mitigate 
adverse consequences of cardiac stress. 
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In addition to impacting the cardiac nervous system, SCS also exerts cardioprotective effects, 
in part, by modulating cardiomyocytes and their response to stress (Ardell and others 2010; 
Southerland and others 2007).  SCS activates intracellular signaling pathways, such as protein kinase 
C (PKC) (Ardell and others 2010; Southerland and others 2007).  Activating PKC pathways is a 
major mediator in preconditioning the heart to reduce the effects of ischemia (Sanada and Kitakaze 
2004; Yellon and Downey 2003).  These mechanisms serve to protect the myocardium from the 
insult of MI (Ardell and others 2010; Sanada and Kitakaze 2004; Southerland and others 2007; 
Yellon and Downey 2003).  The specifics of how SCS-induced cardioprotection is imparted on 
neural and myocyte function is the central focus of this dissertation. 
Neuromodulation of the Ischemic Heart 
SCS Effects on Afferent Transduction 
One theory for the mechanism of action of SCS is that SCS directly activates afferent 
neurons causing them to act in an efferent fashion.  The theory of afferent neurons acting as 
efferents was put forth based on data that SCS-mediated antidromic activation of afferent neurons 
causes the release of neuropeptides in the periphery that induce vasodilation (Horsch and others 
2004; Lembeck and Holzer 1979; Linderoth and others 1994; Tanaka and others 2003; White and 
Helme 1985).  This vasodilation, in turn, salvaged ischemic tissue in a skin flap preparation 
(Linderoth and others 1991; Tanaka and others 2003).  While antidromic activation of afferent fibers 
accounts for peripheral vasodilation for cutaneous tissues, Chapter 3 indicates that SCS does not 
antidromically activate primary cardiac-related afferent neurons (Gherardini and others 1999; 
Horsch and others 2004).  These data point to a different mechanism.  Clinical studies put forth the 
hypothesis that SCS-induced anti-anginal effects by altering supply/demand balance (Linderoth and 
Foreman 1999).  However, subsequent research has demonstrated that thoracic SCS does not induce 
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coronary blood flow changes, at least in a normal heart, and has minimal effects on pressure-volume 
characteristics of the normal or ischemia-stressed heart (Kingma and others 2001).  Yet, SCS does 
blunt MI-induced activation of dorsal column neurons receiving inputs from cardiac nociceptors 
(Ding and others 2008a; Ding and others 2008b).  Based on the studies outlined in Chapter 3, we 
propose the hypothesis that pre-emptive thoracic SCS modifies the milieu of the heart arising in 
response to stress which secondarily alters the sensory transduction of cardiac stress (Armour 2008).  
That is to say, pre-emptive SCS renders cardiomyocytes ischemic-resistant and thereby mitigates the 
MI-induced release of metabolites that activate the cardiac nociceptors. 
SCS Effects on Infarct Size 
While thoracic neuromodulation induces cardioprotective effects, it remained to be 
determined if cervical SCS exerts cardioprotection against the effects of acute MI (Southerland and 
others 2007).  Previous studies showed that pre-emptive thoracic SCS decreased infarct size in 
response to transient MI (Southerland and others 2007).  Previous work also demonstrated that high 
cervical spinal segments modified neural activity in thoracic and lumbar regions of the spinal cord 
arising from peripheral organs (Ding and others 2008a; Ding and others 2008b; Qin and others 
2007a; Qin and others 2008; Qin and others 2007b).  Several mechanisms of the potential 
cardioprotective effects of high cervical SCS were investigated in this dissertation, including the role 
of spinal cord segmental and supraspinal interconnections and their role in modifying adrenergic and 
cholinergic efferent functions. 
Intersegmental communication underlies the ability of high cervical SCS to exert 
cardioprotective effects.  This requirement of intersegmental communication was demonstrated by 
how C6 cervical dorsal column transection eliminated that cardioprotection.  Chapter 2 determined 
for the first time that communication between the cervical and thoracic spinal segments is necessary 
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for cervical SCS to exert its cardioprotective effects (Hua and others 2004a; Hua and others 2004b; 
Qin and others 2004b; Qin and others 2007b).  These data indicate that the upper cervical spinal 
segments may in fact function as a coordinating center for lower spinal cord reflex function with 
respect to the cardiac nervous system (Ding and others 2008a; Ding and others 2008b; Qin and 
others 2007a; Qin and others 2008; Qin and others 2007b). 
High cervical neuromodulation uses peripheral ganglia of the cardiac nervous system to 
induce its cardioprotective effects.  Previous research indicates that intrinsic cardiac ganglia contain 
adrenergic and cholinergic efferents, a fact that Chapter 4 corroborates (Armour 1997; Hoard and 
others 2008; Hoover and others 2009; Singh and others 1999).  Data presented in Chapter 2 
demonstrate that selective blockade of adrenergic receptors or the cholinergic muscarinic receptors 
differentially modifies the ability of C1-C2 SCS to mitigate the MI-induced changes in myocyte 
viability in response to transient MI.  The fact that cervical vagotomy, in contradistinction to 
atropine, produced no change in the ability of SCS to protect myocytes is likely reflective of the 
reflex processing that remains in the peripheral aspect of the cardiac nervous system, even when 
surgically disconnected from higher centers (Ardell and others 1991; Armour 2008; Armour and 
others 2005). 
Previous work has indicated the predominant role of SCS-induced changes in sympathetic 
reflex function in mediating overall cardioprotection (Armour 1997; Armour and others 2005; 
Richer and others 2008).  The ability of selective adrenergic blockade to eliminate the cardiomyocyte 
protective effects of SCS in response to MI substantiates that SCS exerts its effects via modulation 
of adrenergic function using both α- and β-dependent receptors (Southerland and others 2007).  
This adrenergic mediation of SCS cardioprotective effects is substantiated by previous research 
where surgical disruption of the sympathetic afferent/efferent pathways, via transection of the ansae 
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subclavian, eliminates the protective effects of SCS (Cardinal and others 2006; Foreman and others 
2000).  The fact that intrinsic cardiac neurons, of which a large population is local circuit, also 
contain adrenergic receptors suggests that SCS mediates its cardiomyocyte protective effects, in part, 
through modifying neural subtypes at both intracardiac and extracardiac ganglia, as well as at the end 
effectors of the heart (Armour 2008; Armour and others 2002; Cardinal and others 2006; Foreman 
and others 2000; Southerland and others 2007).  Chapter 4 indicates that SCS preferentially modifies 
local circuit neuronal activity without affecting efferent outflow to the heart.  Together, these 
findings implicate the local circuit neurons, which are contained throughout the cardiac nervous 
system, in mediating, in part, the cardiomyocyte protective effects of SCS (Armour 2008). 
In addition to modulation of reflex function within the cardiac nervous system, SCS also 
modulates myocyte function (Southerland and others 2007).  For example, SCS-induced activation 
of the protein kinase C pathways contributes to the infarct reduction associated with pre-emptive 
SCS (Southerland and others 2007).  Other intracellular signaling pathways such as α-adrenoceptor 
coupled PKC pathways and β-adrenoceptor coupled PKA and p38 MAPK pathways, when 
activated can also reduce the lethal effects of MI on cardiomyocytes (Sanada and Kitakaze 2004; 
Tsuchida and others 1994; Yellon and Downey 2003).  The fact that both α- and β-receptor 
blockade blunted SCS-induced reduction in infarct size substantiates this hypothesis. 
The ability of pre-emptive SCS to impact the cardiac myocytes is also demonstrated by the 
modification of the contractility response to acute MI.  While SCS has no discernible effects on 
gross hemodynamics during unstressed states, left ventricular function was significantly improved 
during transient MI when done in the presence of SCS (Foreman and others 2000; Kingma and 
others 2001; Southerland and others 2007).  It remains to be determined if this effect is produced by 
induced changes in neural reflex processing in response to transient MI or if the myocytes are 
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rendered ischemia-resistant by pre-emptive SCS (Kingma and others 2001; Sanada and Kitakaze 
2004; Tsuchida and others 1994; Yellon and Downey 2003). 
 
SCS and the Potential for Ischemia-Induced SCD  
MI-induced changes in cardiac electrical stability involve both intrinsic and extrinsic factors 
(Armour 1999).  Intrinsic effects include alterations in cardiac conduction and induction of ectopic 
pacemakers (Armour 1999).  Extrinsic factors include alterations in autonomic reflex control 
involving both parasympathetic and sympathetic efferent projections (Armour 1999; 2004).  Without 
SCS, atropine evoked minimal changes on the potential for MI-induced ventricular fibrillation.  
Following vagotomy, the potential for MI-induced ventricular fibrillation increased.  This is in 
agreement with previous studies where increased parasympathetic efferent outflow to the heart has 
anti-arrhythmogenic effects (Schultz 2001; Vanoli and others 2008).  By inference therefore, the 
elimination of all centrally-derived parasympathetic efferent outflow should result in the emergence 
of an exaggerated sympathetic efferent reflex response to MI, an effect that would increase lethal 
arrhythmia formation (Chen and others 2001; Schwartz 2001).  With high cervical SCS, atropine 
moderately increased the potential for MI-induced ventricular fibrillation; but cervical vagotomy 
prevented it.  The elimination of lethal arrhythmia formation from cervical vagotomy in the 
presence of MI and SCS likely reflects the reduction in heterogeneity of autonomic inputs to the 
heart coupled with neurally- (sympathetic) induced stabilization of the intrinsic cardiac neuronal 
reflex processing (Armour and others 2002; Foreman and others 2000; Huang and others 1993).  
These data support the theory that SCS-induced stabilization of the cardiac nervous system is 
fundamental to the anti-arrhythmic effects of SCS (Zipes 2008).  These data further indicate that the 
level of SCS influences the involvement of sympathetic versus parasympathetic efferent activity so 
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modulated.  Cervical SCS moderation of cardiac electrical function involves both branches of the 
autonomic nervous system.  Thoracic SCS primarily involves changes in efferent function in 
extrinsic sympathetic and intrinsic cardiac neural systems. 
 
Neuromodulation of arrhythmias 
Arrhythmia formation can result from excessive neuronal input to the intrinsic cardiac 
nervous system (Armour 2004; Armour and others 2005; Cardinal and others 2006; Richer and 
others 2008).  As demonstrated in Chapter 4, excessive neuronal input to the intrinsic cardiac 
nervous system alters the activity patterns of the intrinsic cardiac neurons (Armour and others 2005).  
Global suppression of peripheral autonomic ganglia activity with hexamethonium blunts both the 
neurally evoked response to MSNS and the potential for induction of atrial arrhythmias.  However, 
such a therapeutic approach has limited applicability due to its consequent effect on overall 
cardiovascular control (Armour and others 2005; Miyazaki and others 1989; Randall and others 
1988).  Electrical neuromodulation approach has the potential to evoke more discrete alterations in 
local reflex function without compromising overall cardiovascular control (Armour 2008).  For 
example, modulation of intrinsic cardiac neurons, through blocking either adrenergic or cholinergic 
receptors, modifies the potential for formation of arrhythmias (Armour and others 2005; Richer and 
others 2008).  We suggest that adrenergic/cholinergic receptor-mediated stabilizing effect to induced 
nerve imbalances reflects modulation of neural processing within the intrinsic cardiac nervous 
system.  In support of this hypothesis, Chapter 4 indicates that SCS and hexamethonium modulate 
the intrinsic cardiac neuronal response to MSNS with a corresponding decrease in the potential for 
atrial arrhythmogenesis (Armour 1997; Cardinal and others 2006).  Future studies should focus on 
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the effects of specific receptor agonists and antagonists to modify these neuronal populations and 
their response to evoked stress. 
Conclusions 
This dissertation has determined some of the primary neural mechanisms by which SCS 
neuromodulation-based therapies induces cardioprotection in the stressed heart.  The ability of SCS 
at the cervical spinal segments to reduce the infarct size or potential for SCD has implications for 
future uses of cervical SCS as a potential therapeutic target for treatment of ischemic heart disease.  
The ability of SCS to minimize electrically-induced arrhythmia formation has implications for 
effective treatment of arrhythmia formation of atrial or ventricular origin.  The effects of SCS on 
afferent transduction of ischemic cardiac stress demonstrate the potential of SCS to render 
cardiomyocytes resistant to transient periods of MI.  Together, these data indicate the effectiveness 
of SCS to help maintain a state of homeostasis in the face of the destabilizing effects of cardiac 
disease. 
Topics for Future Study 
Like all research studies, the current study has answered some questions and also elucidated 
topics that need to be investigated.  This is a list of some of those topics: 
 Investigate the effects of selective adrenergic and/or cholinergic receptor blockade on the 
activity of the intrinsic cardiac neurons in response to MSNS-induced AF. 
 Determine how adrenergic receptor systems contribute to the actions of SCS in reducing the 
reflex activation of the intrinsic cardiac neurons in response to MSNS. 
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 Determine the specific neurochemical phenotypes of the intrinsic cardiac neurons and how 
they respond to imbalances in neural inputs, with and without SCS. 
 Determine the specific neurochemical phenotypes of the intrinsic cardiac neurons and how 
they respond to imbalances in the stress of MI, with and without SCS. 
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